Nexalin Technology 株価情報 (NASDAQ: NXL)

最新ニュース Nexalin Technology (NASDAQ:NXL) 株価情報

Nexalin Technology

Nexalin Technology Inc designs and develops innovative neurostimulation products to uniquely and effectively help combat the ongoing global mental health epidemic. The company has developed an easy-to-administer medical device referred to as Generation 1 or Gen-1 that utilizes bioelectronic medical technology to treat anxiety and insomnia, without the need for drugs or psychotherapy. Its original Gen-1 devices are cranial electrotherapy stimulation (CES) devices that emit waveform at 4 milliamps during treatment and are presently classified by the U.S. Food and Drug Administration (FDA) as a Class II device.

Nexalin Technology Inc

NEXLIVING CMNTYS INC by NEXLIVING CMNTYS INC.

Nuix Ltd

Whales with a lot of money to spend have taken a noticeably bullish stance on GE Aero.
Looking at options history for GE Aero (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/GE#NYSE">GE</a>) we detected 27 trades.
If we consider the specifics of each trade, it is accurate to state that 44% of the investors opened trades with bullish expectations and 25% with bearish.
From the overall spotted trades, 18 are puts, for a total amount of $1,174,902 and 9, calls, for a total amount of $272,060.
<h3>Predicted Price Range</h3>
Taking into account the Volume and Open Interest on these contracts, it appears that whales have been targeting a price range from $170.0 to $190.0 for GE Aero over the last 3 months. 
<h3>Volume &amp; Open Interest Development</h3>
Looking at the volume and open interest is a powerful move while trading options. This data can help you track the liquidity and interest for GE Aero's options for a given strike price. Below, we can observe the evolution of the volume and open interest of calls and puts, respectively, for all of GE Aero's whale trades within a strike price range from $170.0 to $190.0 in the last 30 days. 
<h3>GE Aero Call and Put Volume: 30-Day Overview</h3>
<img src="https://www.benzinga.com/files/images/story/2024/1732907742_0.png" alt="Options Call Chart" />
<h3>Largest Options Trades Observed:</h3>

<table>
<thead>
<tr>
<th>Symbol</th>
<th>PUT/CALL</th>
<th>Trade Type</th>
<th>Sentiment</th>
<th>Exp. Date</th>
<th>Ask</th>
<th>Bid</th>
<th>Price</th>
<th>Strike Price</th>
<th>Total Trade Price</th>
<th>Open Interest</th>
<th align="right">Volume</th>
</tr>
</thead>
<tbody>
<tr>
<td>GE</td>
<td>PUT</td>
<td>TRADE</td>
<td>NEUTRAL</td>
<td>01/17/25</td>
<td>$3.75</td>
<td>$3.6</td>
<td>$3.68</td>
<td>$175.00</td>
<td>$170.0K</td>
<td>2.0K</td>
<td align="right">554</td>
</tr>
<tr>
<td>GE</td>
<td>PUT</td>
<td>TRADE</td>
<td>BULLISH</td>
<td>02/21/25</td>
<td>$13.9</td>
<td>$13.7</td>
<td>$13.78</td>
<td>$190.00</td>
<td>$75.7K</td>
<td>137</td>
<td align="right">620</td>
</tr>
<tr>
<td>GE</td>
<td>PUT</td>
<td>SWEEP</td>
<td>BULLISH</td>
<td>02/21/25</td>
<td>$13.9</td>
<td>$13.7</td>
<td>$13.79</td>
<td>$190.00</td>
<td>$75.5K</td>
<td>137</td>
<td align="right">565</td>
</tr>
<tr>
<td>GE</td>
<td>PUT</td>
<td>SWEEP</td>
<td>NEUTRAL</td>
<td>02/21/25</td>
<td>$13.75</td>
<td>$13.7</td>
<td>$13.75</td>
<td>$190.00</td>
<td>$75.3K</td>
<td>137</td>
<td align="right">675</td>
</tr>
<tr>
<td>GE</td>
<td>PUT</td>
<td>SWEEP</td>
<td>NEUTRAL</td>
<td>02/21/25</td>
<td>$14.2</td>
<td>$13.9</td>
<td>$14.05</td>
<td>$190.00</td>
<td>$69.6K</td>
<td>137</td>
<td align="right">280</td>
</tr>
</tbody>
</table>

<h3>About GE Aero</h3>
GE Aerospace is the global leader in designing, manufacturing, and servicing large aircraft engines, along with partner Safran in their CFM joint venture. With its massive global installed base of nearly 70,000 commercial and military engines, GE Aerospace earns most of its profits on recurring service revenue of that equipment, which operates for decades. GE Aerospace is the remaining core business of the company formed in 1892 with historical ties to American inventor Thomas Edison; that company became a storied conglomerate with peak revenue of $130 billion in 2000. GE spun off its appliance, finance, healthcare, and wind and power businesses between 2016 and 2024.
After a thorough review of the options trading surrounding GE Aero, we move to examine the company in more detail. This includes an assessment of its current market status and performance.
<h3>GE Aero's Current Market Status</h3>
<ul>
<li>With a trading volume of 2,051,996, the price of GE is up by 0.86%, reaching $182.16.</li>
<li>Current RSI values indicate that the stock is may be approaching overbought.</li>
<li>Next earnings report is scheduled for 53 days from now.</li>
</ul>
Unusual Options Activity Detected: Smart Money on the Move
Benzinga Edge's Unusual Options board spots potential market movers before they happen. See what positions big money is taking on your favorite stocks. <a href="https://www.benzinga.com/premium/ideas/benzinga-edge-checkout/?t=Be8be9arja3be22bz20&amp;utm_source=benzinga-insights">Click here for access</a>.
Options are a riskier asset compared to just trading the stock, but they have higher profit potential. Serious options traders manage this risk by educating themselves daily, scaling in and out of trades, following more than one indicator, and following the markets closely.
If you want to stay updated on the latest options trades for GE Aero, <a href="https://benzinga.grsm.io/register174">Benzinga Pro</a> gives you real-time options trades alerts.

Options

Markets

GE Aero's Options Frenzy: What You Need to Know

Investors with a lot of money to spend have taken a bearish stance on AbbVie (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ABBV#NYSE">ABBV</a>).
And retail traders should know.
We noticed this today when the trades showed up on publicly available options history that we track here at Benzinga.
Whether these are institutions or just wealthy individuals, we don't know. But when something this big happens with ABBV, it often means somebody knows something is about to happen.
So how do we know what these investors just did? 
Today, <a href="https://pro.benzinga.com/?utm_source=insights">Benzinga</a>'s options scanner spotted 8 uncommon options trades for AbbVie.
This isn't normal.
The overall sentiment of these big-money traders is split between 25% bullish and 75%, bearish.
Out of all of the special options we uncovered, 2 are puts, for a total amount of $212,565, and 6 are calls, for a total amount of $256,922.
<h3>What's The Price Target?</h3>
After evaluating the trading volumes and Open Interest, it's evident that the major market movers are focusing on a price band between $175.0 and $190.0 for AbbVie, spanning the last three months.
<h3>Analyzing Volume &amp; Open Interest</h3>
Looking at the volume and open interest is an insightful way to conduct due diligence on a stock.
This data can help you track the liquidity and interest for AbbVie's options for a given strike price.
Below, we can observe the evolution of the volume and open interest of calls and puts, respectively, for all of AbbVie's whale activity within a strike price range from $175.0 to $190.0 in the last 30 days. 
<h3>AbbVie Option Activity Analysis: Last 30 Days</h3>
<img src="https://www.benzinga.com/files/images/story/2024/1732907738_0.png" alt="Options Call Chart" />
<h3>Largest Options Trades Observed:</h3>

<table>
<thead>
<tr>
<th>Symbol</th>
<th>PUT/CALL</th>
<th>Trade Type</th>
<th>Sentiment</th>
<th>Exp. Date</th>
<th>Ask</th>
<th>Bid</th>
<th>Price</th>
<th>Strike Price</th>
<th>Total Trade Price</th>
<th>Open Interest</th>
<th align="right">Volume</th>
</tr>
</thead>
<tbody>
<tr>
<td>ABBV</td>
<td>PUT</td>
<td>SWEEP</td>
<td>BEARISH</td>
<td>01/16/26</td>
<td>$20.1</td>
<td>$20.0</td>
<td>$20.05</td>
<td>$190.00</td>
<td>$174.4K</td>
<td>664</td>
<td align="right">87</td>
</tr>
<tr>
<td>ABBV</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BULLISH</td>
<td>12/20/24</td>
<td>$1.93</td>
<td>$1.66</td>
<td>$1.66</td>
<td>$187.50</td>
<td>$70.0K</td>
<td>447</td>
<td align="right">431</td>
</tr>
<tr>
<td>ABBV</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BEARISH</td>
<td>02/21/25</td>
<td>$9.6</td>
<td>$9.35</td>
<td>$9.35</td>
<td>$180.00</td>
<td>$44.8K</td>
<td>1.8K</td>
<td align="right">58</td>
</tr>
<tr>
<td>ABBV</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BEARISH</td>
<td>02/21/25</td>
<td>$9.85</td>
<td>$9.7</td>
<td>$9.7</td>
<td>$180.00</td>
<td>$42.6K</td>
<td>1.8K</td>
<td align="right">78</td>
</tr>
<tr>
<td>ABBV</td>
<td>CALL</td>
<td>TRADE</td>
<td>BEARISH</td>
<td>11/29/24</td>
<td>$9.4</td>
<td>$7.55</td>
<td>$8.26</td>
<td>$175.00</td>
<td>$41.3K</td>
<td>481</td>
<td align="right">77</td>
</tr>
</tbody>
</table>

<h3>About AbbVie</h3>
AbbVie is a pharmaceutical firm with a strong exposure to immunology (with Humira, Skyrizi, and Rinvoq) and oncology (with Imbruvica and Venclexta). The company was spun off from Abbott in early 2013. The 2020 acquisition of Allergan added several new products and drugs in aesthetics (including Botox).
<h3>Present Market Standing of AbbVie</h3>
<ul>
<li>With a volume of 2,710,151, the price of ABBV is down -0.11% at $182.88. </li>
<li>RSI indicators hint that the underlying stock may be approaching oversold.</li>
<li>Next earnings are expected to be released in 63 days.</li>
</ul>
Unusual Options Activity Detected: Smart Money on the Move
Benzinga Edge's Unusual Options board spots potential market movers before they happen. See what positions big money is taking on your favorite stocks. <a href="https://www.benzinga.com/premium/ideas/benzinga-edge-checkout/?t=Be8be9arja3be22bz20&amp;utm_source=benzinga-insights">Click here for access</a>.
Options are a riskier asset compared to just trading the stock, but they have higher profit potential. Serious options traders manage this risk by educating themselves daily, scaling in and out of trades, following more than one indicator, and following the markets closely.
If you want to stay updated on the latest options trades for AbbVie, <a href="https://benzinga.grsm.io/register174">Benzinga Pro</a> gives you real-time options trades alerts.

ABBV

Spotlight on AbbVie: Analyzing the Surge in Options Activity

High-rolling investors have positioned themselves bearish on Teva Pharmaceutical Indus (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/TEVA#NYSE">TEVA</a>), and it's important for retail traders to take note. 
\This activity came to our attention today through Benzinga's tracking of publicly available options data. The identities of these investors are uncertain, but such a significant move in TEVA often signals that someone has privileged information.
Today, Benzinga's options scanner spotted 25 options trades for Teva Pharmaceutical Indus. This is not a typical pattern.
The sentiment among these major traders is split, with 24% bullish and 60% bearish. Among all the options we identified, there was one put, amounting to $48,400, and 24 calls, totaling $1,648,118.
<h3>Expected Price Movements</h3>
Analyzing the Volume and Open Interest in these contracts, it seems that the big players have been eyeing a price window from $17.0 to $30.0 for Teva Pharmaceutical Indus during the past quarter. 
<h3>Volume &amp; Open Interest Development</h3>
Assessing the volume and open interest is a strategic step in options trading. These metrics shed light on the liquidity and investor interest in Teva Pharmaceutical Indus's options at specified strike prices. The forthcoming data visualizes the fluctuation in volume and open interest for both calls and puts, linked to Teva Pharmaceutical Indus's substantial trades, within a strike price spectrum from $17.0 to $30.0 over the preceding 30 days.
<h3>Teva Pharmaceutical Indus Call and Put Volume: 30-Day Overview</h3>
<img src="https://www.benzinga.com/files/images/story/2024/1732907733_0.png" alt="Options Call Chart" />
<h3>Significant Options Trades Detected:</h3>

<table>
<thead>
<tr>
<th>Symbol</th>
<th>PUT/CALL</th>
<th>Trade Type</th>
<th>Sentiment</th>
<th>Exp. Date</th>
<th>Ask</th>
<th>Bid</th>
<th>Price</th>
<th>Strike Price</th>
<th>Total Trade Price</th>
<th>Open Interest</th>
<th>Volume</th>
</tr>
</thead>
<tbody>
<tr>
<td>TEVA</td>
<td>CALL</td>
<td>TRADE</td>
<td>BULLISH</td>
<td>06/20/25</td>
<td>$0.61</td>
<td>$0.23</td>
<td>$0.55</td>
<td>$23.00</td>
<td>$418.3K</td>
<td>30</td>
<td>20.0K</td>
</tr>
<tr>
<td>TEVA</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BULLISH</td>
<td>06/20/25</td>
<td>$0.4</td>
<td>$0.2</td>
<td>$0.33</td>
<td>$25.00</td>
<td>$117.1K</td>
<td>17</td>
<td>18.5K</td>
</tr>
<tr>
<td>TEVA</td>
<td>CALL</td>
<td>SWEEP</td>
<td>NEUTRAL</td>
<td>06/20/25</td>
<td>$0.45</td>
<td>$0.43</td>
<td>$0.43</td>
<td>$23.00</td>
<td>$107.2K</td>
<td>30</td>
<td>9.9K</td>
</tr>
<tr>
<td>TEVA</td>
<td>CALL</td>
<td>TRADE</td>
<td>BULLISH</td>
<td>06/20/25</td>
<td>$0.55</td>
<td>$0.23</td>
<td>$0.55</td>
<td>$23.00</td>
<td>$85.2K</td>
<td>30</td>
<td>21.5K</td>
</tr>
<tr>
<td>TEVA</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BEARISH</td>
<td>03/21/25</td>
<td>$0.25</td>
<td>$0.23</td>
<td>$0.23</td>
<td>$22.00</td>
<td>$67.9K</td>
<td>22.5K</td>
<td>13.4K</td>
</tr>
</tbody>
</table>

<h3>About Teva Pharmaceutical Indus</h3>
Teva Pharmaceutical Industries, based in Israel, is the leading generic drug manufacturer in the world. Teva derives half of its sales from North America and makes up a high-single-digit percentage of the total number of generic prescriptions in the US. It also has a significant presence in Europe, Japan, Russia, and Israel. Besides generics, Teva has a portfolio of innovative medicines and biosimilars in three main therapeutic areas: central nervous system with Copaxone, Ajovy, and Austedo; respiratory with Qvar and ProAir; and oncology with Truxima, Herzuma, and Bendeka/Treanda. Teva also sells active pharmaceutical ingredients, offers contract manufacturing services, and owns Anda, a US-based generic and specialty drug distributor.
After a thorough review of the options trading surrounding Teva Pharmaceutical Indus, we move to examine the company in more detail. This includes an assessment of its current market status and performance.
<h3>Present Market Standing of Teva Pharmaceutical Indus</h3>
<ul>
<li>With a trading volume of 5,067,042, the price of TEVA is up by 0.3%, reaching $16.62.</li>
<li>Current RSI values indicate that the stock is may be approaching oversold.</li>
<li>Next earnings report is scheduled for 61 days from now.</li>
</ul>
Turn $1000 into $1270 in just 20 days?
20-year pro options trader reveals his one-line chart technique that shows when to buy and sell. Copy his trades, which have had averaged a 27% profit every 20 days. <a href="https://www.benzinga.com/premium/ideas/options-moneyline-2/?t=Moop1arja3be22op14&amp;utm_source=benzinga-insights">Click here for access</a>.
Trading options involves greater risks but also offers the potential for higher profits. Savvy traders mitigate these risks through ongoing education, strategic trade adjustments, utilizing various indicators, and staying attuned to market dynamics. Keep up with the latest options trades for Teva Pharmaceutical Indus with <a href="https://benzinga.grsm.io/register174">Benzinga Pro</a> for real-time alerts.

TEVA

Teva Pharmaceutical Indus Unusual Options Activity

Salesforce, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CRM#NYSE">CRM</a>) will release earnings results for the third quarter, after the <a href="https://www.benzinga.com/quote/crm/earnings">closing bell, on Tuesday, Dec. 3</a>.
Analysts expect the San Francisco, California-based company to report quarterly earnings at $2.44 per share, up from $2.11 per share in the year-ago period. Salesforce projects to report quarterly revenue of $9.35 billion, compared to $8.72 billion a year earlier, according to data from <a href="https://pro.benzinga.com/dashboard">Benzinga Pro.</a>
On Nov. 27, Citigroup analyst Tyler Radke maintained Salesforce with a Neutral and raised the price target from $290 to $368.
With the recent buzz around Salesforce ahead of quarterly earnings, some investors may be eyeing potential gains from the company's dividends too. As of now, Salesforce offers an annual dividend yield of 0.48%, which is a quarterly dividend amount of 40 cents per share ($1.60 a year).
To figure out how to earn $500 monthly from Salesforce, we start with the yearly target of $6,000 ($500 x 12 months).
Next, we take this amount and divide it by Salesforce's $1.60 dividend: $6,000 / $1.60 = 3,750 shares.
So, an investor would need to own approximately $1,237,538 worth of Salesforce, or 3,750 shares to generate a monthly dividend income of $500.
Assuming a more conservative goal of $100 monthly ($1,200 annually), we do the same calculation: $1,200 / $1.60 = 750 shares, or $247,508 to generate a monthly dividend income of $100.
Note that dividend yield can change on a rolling basis, as the dividend payment and the stock price both fluctuate over time.
The dividend yield is calculated by dividing the annual dividend payment by the current stock price. As the stock price changes, the dividend yield will also change.
For example, if a stock pays an annual dividend of $2 and its current price is $50, its dividend yield would be 4%. However, if the stock price increases to $60, the dividend yield would decrease to 3.33% ($2/$60).
Conversely, if the stock price decreases to $40, the dividend yield would increase to 5% ($2/$40).
Further, the dividend payment itself can also change over time, which can also impact the dividend yield. If a company increases its dividend payment, the dividend yield will increase even if the stock price remains the same. Similarly, if a company decreases its dividend payment, the dividend yield will decrease.
CRM Price Action: Shares of Salesforce closed slightly lower at $329.99 Friday. 
<figure class="wp-block-embed is-type-video is-provider-youtube wp-block-embed-youtube wp-embed-aspect-16-9 wp-has-aspect-ratio"> 
<div class="wp-block-embed__wrapper">
<iframe loading="lazy" title="How to Find Dividend Stocks: Scan, Analyze, and Capture with Benzinga Pro" width="500" height="281" src="https://www.youtube.com/embed/pVF0O2lsEH4?feature=oembed" frameborder="0" allow="accelerometer; autoplay; clipboard-write; encrypted-media; gyroscope; picture-in-picture; web-share" referrerpolicy="strict-origin-when-cross-origin" allowfullscreen></iframe>
</div>
</figure>
Read More: 
<ul>
<li><a href="https://www.benzinga.com/markets/24/11/42221018/jim-cramer-reddit-is-fabulous-dow-is-a-tough-one">Jim Cramer: Reddit Is &#8216;Fabulous,&#8217; Dow Is A &#8216;Tough&#8217; One</a></li>
</ul>
Photo: Shutterstock

How To Earn $500 A Month From Salesforce Stock Ahead Of Q3 Earnings

The <a href="https://www.benzinga.com/topic/esg">ESG investing space</a> had its ups and downs in 2024. Sustainable assets saw a 7% increase in AUM to $3.2 billion.
While the year has been challenging for ESG equity funds, particularly with underperformance in the first half, JPMorgan analysts are looking to 2025 with optimism. 
Among the most promising picks are bonds from major renewable energy players. These bonds are poised to benefit from tax credits, policy shifts, and growing demand for clean energy:
<ul>
<li>NextEra Energy Inc (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/NEE#NYSE">NEE</a>) – $5.25% 03/15/34 Bond (Z-spread 132bp): As one of the largest developers of renewable energy in the US, NextEra Energy continues to be a top pick for investors focused on ESG. The company remains exposed to fluctuations in renewable tax credits and financing, but with strong customer demand and state carbon targets, its long-term prospects are solid. This bond offers a potential upside as NextEra continues to expand its solar and wind portfolios.</li>
<li>The AES Corp (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/AES#NYSE">AES</a>) – $2.45% 01/15/31 Green Bond (Z-spread 168bp): AES is another key player in the renewable energy space, benefiting from a large backlog of utility-scale projects. The company is positioned to capitalize on renewable PTCs, ITCs, and tax equity financing. With data center offtakers less sensitive to price hikes and interest rates, AES is well-positioned to navigate potential policy changes and remain a solid investment for ESG-focused bondholders.</li>
<li>Constellation Energy Corp (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CEG#NASDAQ">CEG</a>) – $5.75% 03/15/54 Green Bond (Z-spread 190bp): As a leader in nuclear energy, Constellation Energy is supported by strong power fundamentals and firm nuclear sentiment across both sides of the legislature. With continued demand for reliable power and a growing market for data centers, Constellation is poised to benefit from its nuclear and renewable energy mix. This bond stands out as an attractive option for ESG investors looking for stable returns in the energy sector.</li>
</ul>
<h2 class="wp-block-heading">ESG Bonds Set To Shine In 2025</h2>
JPMorgan's ESG bond picks for 2025 focus on companies in the renewable energy and utilities sectors. These bonds are positioned to benefit from strong macroeconomic support and evolving policies favoring clean energy.
With growing demand for green energy and stable regulatory environments, bonds from NextEra, AES, and Constellation Energy are likely to be top picks for ESG-focused investors looking for solid returns in the coming year.
Read Next: 
<ul>
<li><a href="https://www.benzinga.com/government/regulations/24/11/41926301/sustainable-investment-under-trump-performance-matters-far-more-than-politics-jpmorgan-analyst-says">Sustainable Investment Under Trump: &#8216;Performance Matters Far More Than Politics,&#8217; JPMorgan Analyst Says</a></li>
</ul>
Image: Shutterstock

Analyst Color

Long Ideas

Bonds

Analyst Ratings

Trading Ideas

NextEra, AES, Constellation: JPMorgan's Top ESG Bond Picks For 2025

4 analysts have expressed a variety of opinions on RadNet (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RDNT#NASDAQ">RDNT</a>) over the past quarter, offering a diverse set of opinions from bullish to bearish.
The table below provides a snapshot of their recent ratings, showcasing how sentiments have evolved over the past 30 days and comparing them to the preceding months.
<table>
<thead>
<tr>
<th></th>
<th align="right">Bullish</th>
<th align="right">Somewhat Bullish</th>
<th align="right">Indifferent</th>
<th align="right">Somewhat Bearish</th>
<th align="right">Bearish</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total Ratings</td>
<td align="right">3</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>Last 30D</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>1M Ago</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>2M Ago</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>3M Ago</td>
<td align="right">2</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
</tbody>
</table>
Analysts provide deeper insights through their assessments of 12-month price targets, revealing an average target of $83.25, a high estimate of $94.00, and a low estimate of $79.00. Witnessing a positive shift, the current average has risen by 18.09% from the previous average price target of $70.50.
<img src="https://www.benzinga.com/files/images/story/2024/1732906829_0.png" alt="price target chart" />
<h2>Analyzing Analyst Ratings: A Detailed Breakdown</h2>
In examining recent analyst actions, we gain insights into how financial experts perceive RadNet. The following summary outlines key analysts, their recent evaluations, and adjustments to ratings and price targets.
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>David Macdonald</td>
<td>Truist Securities</td>
<td>Raises</td>
<td>Buy</td>
<td>$94.00</td>
<td>$80.00</td>
</tr>
<tr>
<td>David Macdonald</td>
<td>Truist Securities</td>
<td>Raises</td>
<td>Buy</td>
<td>$80.00</td>
<td>$70.00</td>
</tr>
<tr>
<td>Brian Tanquilut</td>
<td>Jefferies</td>
<td>Raises</td>
<td>Buy</td>
<td>$80.00</td>
<td>$75.00</td>
</tr>
<tr>
<td>Andrew Mok</td>
<td>Barclays</td>
<td>Raises</td>
<td>Overweight</td>
<td>$79.00</td>
<td>$57.00</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li>Action Taken: In response to dynamic market conditions and company performance, analysts update their recommendations. Whether they 'Maintain', 'Raise', or 'Lower' their stance, it signifies their reaction to recent developments related to RadNet. This insight gives a snapshot of analysts' perspectives on the current state of the company.</li>
<li>Rating: Analysts unravel qualitative evaluations for stocks, ranging from 'Outperform' to 'Underperform'. These ratings offer insights into expectations for the relative performance of RadNet compared to the broader market.</li>
<li>Price Targets: Analysts gauge the dynamics of price targets, providing estimates for the future value of RadNet's stock. This comparison reveals trends in analysts' expectations over time.</li>
</ul>
Understanding these analyst evaluations alongside key financial indicators can offer valuable insights into RadNet's market standing. Stay informed and make well-considered decisions with our Ratings Table.
<a href="https://www.benzinga.com/quote/RDNT/analyst-ratings?utm_source=Benzinga Insights">Stay up to date on RadNet analyst ratings.</a>
<h2>Get to Know RadNet Better</h2>
RadNet Inc is a national provider of diagnostic imaging services that operates in two business segments; The Imaging Center segment provides physicians with imaging capabilities to facilitate the diagnosis and treatment of diseases and disorders. Services include magnetic resonance imaging (MRI), computed tomography (CT), positron emission tomography (PET), nuclear medicine, mammography, ultrasound, diagnostic radiology (X-ray), fluoroscopy and other related procedures, and Artificial Intelligence segment develops and deploys clinical applications to enhance interpretation of medical images and improve patient outcomes with an emphasis on brain, breast, prostate, and pulmonary diagnostics. The company derives a majority of its revenue from the Imaging center segment.
<h3>Breaking Down RadNet's Financial Performance</h3>
Market Capitalization Perspectives: The company's market capitalization falls below industry averages, signaling a relatively smaller size compared to peers. This positioning may be influenced by factors such as perceived growth potential or operational scale.
Revenue Growth: RadNet displayed positive results in 3 months. As of 30 September, 2024, the company achieved a solid revenue growth rate of approximately 14.72%. This indicates a notable increase in the company's top-line earnings. When compared to others in the Health Care sector, the company excelled with a growth rate higher than the average among peers.
Net Margin: RadNet's net margin falls below industry averages, indicating challenges in achieving strong profitability. With a net margin of 0.7%, the company may face hurdles in effective cost management.
Return on Equity (ROE): The company's ROE is below industry benchmarks, signaling potential difficulties in efficiently using equity capital. With an ROE of 0.36%, the company may need to address challenges in generating satisfactory returns for shareholders.
Return on Assets (ROA): RadNet's ROA is below industry standards, pointing towards difficulties in efficiently utilizing assets. With an ROA of 0.1%, the company may encounter challenges in delivering satisfactory returns from its assets.
Debt Management: RadNet's debt-to-equity ratio is below the industry average. With a ratio of 1.94, the company relies less on debt financing, maintaining a healthier balance between debt and equity, which can be viewed positively by investors.
<h2>How Are Analyst Ratings Determined?</h2>
Ratings come from analysts, or specialists within banking and financial systems that report for specific stocks or defined sectors (typically once per quarter for each stock). Analysts usually derive their information from company conference calls and meetings, financial statements, and conversations with important insiders to reach their decisions.
Some analysts publish their predictions for metrics such as growth estimates, earnings, and revenue to provide additional guidance with their ratings. When using analyst ratings, it is important to keep in mind that stock and sector analysts are also human and are only offering their opinions to investors.
Which Stocks Are Analysts Recommending Now?
Benzinga Edge gives you instant access to all major analyst upgrades, downgrades, and price targets. Sort by accuracy, upside potential, and more. <a href="https://www.benzinga.com/premium/ideas/benzinga-edge-checkout/?t=be8be9arja3be22bz21&amp;utm_source=benzinga-insights">Click here to stay ahead of the market</a>.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

RDNT

Analyst Scoreboard: 4 Ratings For RadNet

HP's (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/HPQ#NYSE">HPQ</a>) short percent of float has fallen 14.74% since its last report. The company recently reported that it has 38.06 million shares sold short, which is 4.51% of all regular shares that are available for trading. Based on its trading volume, it would take traders 5.42 days to cover their short positions on average.
<h3>Why Short Interest Matters</h3>
Short interest is the number of shares that have been sold short but have not yet been covered or closed out. <a href="https://www.benzinga.com/money/how-to-short-a-stock/">Short selling</a> is when a trader sells shares of a company they do not own, with the hope that the price will fall. Traders make money from short selling if the price of the stock falls and they lose if it rises.
Short interest is important to track because it can act as an indicator of market sentiment towards a particular stock. An increase in short interest can signal that investors have become more bearish, while a decrease in short interest can signal they have become more bullish.
See Also: <a href="https://www.benzinga.com/short-interest">List of the most shorted stocks</a>
<h3>HP Short Interest Graph (3 Months)</h3>
<img src="https://www.benzinga.com/files/images/story/2024/1732906822_0.png" alt="short_fig" />
As you can see from the chart above the percentage of shares that are sold short for HP has declined since its last report. This does not mean that the stock is going to rise in the near-term but traders should be aware that less shares are being shorted.
<h3>Comparing HP's Short Interest Against Its Peers</h3>
Peer comparison is a popular technique amongst analysts and investors for gauging how well a company is performing. A company's peer is another company that has similar characteristics to it, such as industry, size, age, and financial structure. You can find a company's peer group by reading its 10-K, proxy filing, or by doing your own similarity analysis.
According to <a href="https://pro.benzinga.com/">Benzinga Pro</a>, HP's peer group average for short interest as a percentage of float is 6.95%, which means the company has less short interest than most of its peers.
Did you know that increasing short interest can actually be bullish for a stock? <a href="https://www.benzinga.com/money/how-to-make-money-on-a-short-squeeze/">This post by Benzinga Money explains how you can profit from it.</a>
This article was generated by Benzinga's automated content engine and was reviewed by an editor.

Short Sellers

Short Ideas

(HPQ) - Analyzing HP's Short Interest

GE HealthCare Techs's (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/GEHC#NYSE">GEHC</a>) short percent of float has risen 5.19% since its last report. The company recently reported that it has 8.72 million shares sold short, which is 2.43% of all regular shares that are available for trading. Based on its trading volume, it would take traders 2.36 days to cover their short positions on average.
<h3>Why Short Interest Matters</h3>
Short interest is the number of shares that have been sold short but have not yet been covered or closed out. <a href="https://www.benzinga.com/money/how-to-short-a-stock/">Short selling</a> is when a trader sells shares of a company they do not own, with the hope that the price will fall. Traders make money from short selling if the price of the stock falls and they lose if it rises.
Short interest is important to track because it can act as an indicator of market sentiment towards a particular stock. An increase in short interest can signal that investors have become more bearish, while a decrease in short interest can signal they have become more bullish.
See Also: <a href="https://www.benzinga.com/short-interest">List of the most shorted stocks</a>
<h3>GE HealthCare Techs Short Interest Graph (3 Months)</h3>
<img src="https://www.benzinga.com/files/images/story/2024/1732906816_0.png" alt="short_fig" />
As you can see from the chart above the percentage of shares that are sold short for GE HealthCare Techs has grown since its last report. This does not mean that the stock is going to fall in the near-term but traders should be aware that more shares are being shorted.
<h3>Comparing GE HealthCare Techs's Short Interest Against Its Peers</h3>
Peer comparison is a popular technique amongst analysts and investors for gauging how well a company is performing. A company's peer is another company that has similar characteristics to it, such as industry, size, age, and financial structure. You can find a company's peer group by reading its 10-K, proxy filing, or by doing your own similarity analysis.
According to <a href="https://pro.benzinga.com/">Benzinga Pro</a>, GE HealthCare Techs's peer group average for short interest as a percentage of float is 3.98%, which means the company has less short interest than most of its peers.
Did you know that increasing short interest can actually be bullish for a stock? <a href="https://www.benzinga.com/money/how-to-make-money-on-a-short-squeeze/">This post by Benzinga Money explains how you can profit from it.</a>
This article was generated by Benzinga's automated content engine and was reviewed by an editor.

GEHC

Peering Into GE HealthCare Techs's Recent Short Interest

Providing a diverse range of perspectives from bullish to bearish, 18 analysts have published ratings on Applied Mat (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AMAT#NASDAQ">AMAT</a>) in the last three months.
In the table below, you'll find a summary of their recent ratings, revealing the shifting sentiments over the past 30 days and comparing them to the previous months.
<table>
<thead>
<tr>
<th></th>
<th align="right">Bullish</th>
<th align="right">Somewhat Bullish</th>
<th align="right">Indifferent</th>
<th align="right">Somewhat Bearish</th>
<th align="right">Bearish</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total Ratings</td>
<td align="right">5</td>
<td align="right">7</td>
<td align="right">6</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>Last 30D</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>1M Ago</td>
<td align="right">4</td>
<td align="right">3</td>
<td align="right">3</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>2M Ago</td>
<td align="right">0</td>
<td align="right">2</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>3M Ago</td>
<td align="right">1</td>
<td align="right">1</td>
<td align="right">2</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
</tbody>
</table>
Analysts have recently evaluated Applied Mat and provided 12-month price targets. The average target is $217.0, accompanied by a high estimate of $250.00 and a low estimate of $170.00. A negative shift in sentiment is evident as analysts have decreased the average price target by 6.87%. 
<img src="https://www.benzinga.com/files/images/story/2024/1732906814_0.png" alt="price target chart" />
<h2>Exploring Analyst Ratings: An In-Depth Overview</h2>
The standing of Applied Mat among financial experts is revealed through an in-depth exploration of recent analyst actions. The summary below outlines key analysts, their recent evaluations, and adjustments to ratings and price targets.
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Stacy Rasgon</td>
<td>Bernstein</td>
<td>Lowers</td>
<td>Outperform</td>
<td>$210.00</td>
<td>$220.00</td>
</tr>
<tr>
<td>Krish Sankar</td>
<td>TD Cowen</td>
<td>Lowers</td>
<td>Buy</td>
<td>$230.00</td>
<td>$250.00</td>
</tr>
<tr>
<td>C J Muse</td>
<td>Cantor Fitzgerald</td>
<td>Maintains</td>
<td>Overweight</td>
<td>$250.00</td>
<td>$250.00</td>
</tr>
<tr>
<td>Mark Lipacis</td>
<td>Evercore ISI Group</td>
<td>Lowers</td>
<td>Outperform</td>
<td>$250.00</td>
<td>$260.00</td>
</tr>
<tr>
<td>Joseph Quatrochi</td>
<td>Wells Fargo</td>
<td>Lowers</td>
<td>Overweight</td>
<td>$220.00</td>
<td>$235.00</td>
</tr>
<tr>
<td>Vivek Arya</td>
<td>B of A Securities</td>
<td>Lowers</td>
<td>Buy</td>
<td>$210.00</td>
<td>$220.00</td>
</tr>
<tr>
<td>Joseph Moore</td>
<td>Morgan Stanley</td>
<td>Lowers</td>
<td>Equal-Weight</td>
<td>$179.00</td>
<td>$185.00</td>
</tr>
<tr>
<td>Sidney Ho</td>
<td>Deutsche Bank</td>
<td>Lowers</td>
<td>Hold</td>
<td>$200.00</td>
<td>$220.00</td>
</tr>
<tr>
<td>Charles Shi</td>
<td>Needham</td>
<td>Lowers</td>
<td>Buy</td>
<td>$225.00</td>
<td>$240.00</td>
</tr>
<tr>
<td>Brian Chin</td>
<td>Stifel</td>
<td>Lowers</td>
<td>Buy</td>
<td>$250.00</td>
<td>$270.00</td>
</tr>
<tr>
<td>Mehdi Hosseini</td>
<td>Susquehanna</td>
<td>Lowers</td>
<td>Neutral</td>
<td>$170.00</td>
<td>$190.00</td>
</tr>
<tr>
<td>Mehdi Hosseini</td>
<td>Susquehanna</td>
<td>Lowers</td>
<td>Neutral</td>
<td>$190.00</td>
<td>$215.00</td>
</tr>
<tr>
<td>C J Muse</td>
<td>Cantor Fitzgerald</td>
<td>Maintains</td>
<td>Overweight</td>
<td>$250.00</td>
<td>$250.00</td>
</tr>
<tr>
<td>Joseph Quatrochi</td>
<td>Wells Fargo</td>
<td>Lowers</td>
<td>Overweight</td>
<td>$235.00</td>
<td>$260.00</td>
</tr>
<tr>
<td>Vijay Rakesh</td>
<td>Mizuho</td>
<td>Lowers</td>
<td>Outperform</td>
<td>$225.00</td>
<td>$245.00</td>
</tr>
<tr>
<td>Joseph Moore</td>
<td>Morgan Stanley</td>
<td>Lowers</td>
<td>Equal-Weight</td>
<td>$185.00</td>
<td>$224.00</td>
</tr>
<tr>
<td>Atif Malik</td>
<td>Citigroup</td>
<td>Lowers</td>
<td>Buy</td>
<td>$217.00</td>
<td>$240.00</td>
</tr>
<tr>
<td>Timothy Arcuri</td>
<td>UBS</td>
<td>Lowers</td>
<td>Neutral</td>
<td>$210.00</td>
<td>$220.00</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li>Action Taken: Analysts respond to changes in market conditions and company performance, frequently updating their recommendations. Whether they 'Maintain', 'Raise' or 'Lower' their stance, it reflects their reaction to recent developments related to Applied Mat. This information offers a snapshot of how analysts perceive the current state of the company.</li>
<li>Rating: Providing a comprehensive analysis, analysts offer qualitative assessments, ranging from 'Outperform' to 'Underperform'. These ratings reflect expectations for the relative performance of Applied Mat compared to the broader market.</li>
<li>Price Targets: Analysts predict movements in price targets, offering estimates for Applied Mat's future value. Examining the current and prior targets offers insights into analysts' evolving expectations.</li>
</ul>
Assessing these analyst evaluations alongside crucial financial indicators can provide a comprehensive overview of Applied Mat's market position. Stay informed and make well-judged decisions with the assistance of our Ratings Table.
<a href="https://www.benzinga.com/quote/AMAT/analyst-ratings?utm_source=Benzinga Insights">Stay up to date on Applied Mat analyst ratings.</a>
<h2>About Applied Mat</h2>
Applied Materials is the largest semiconductor wafer fabrication equipment, or WFE, manufacturer in the world. Applied Materials has a broad portfolio spanning nearly every corner of the WFE ecosystem. Specifically, Applied Materials holds a market share leadership position in deposition, which entails the layering of new materials on semiconductor wafers. It is more exposed to general-purpose logic chips made at integrated device manufacturers and foundries. It counts the largest chipmakers in the world as customers, including TSMC, Intel, and Samsung.
<h3>Applied Mat's Economic Impact: An Analysis</h3>
Market Capitalization Analysis: The company's market capitalization surpasses industry averages, showcasing a dominant size relative to peers and suggesting a strong market position.
Revenue Growth: Applied Mat displayed positive results in 3 months. As of 31 October, 2024, the company achieved a solid revenue growth rate of approximately 3.94%. This indicates a notable increase in the company's top-line earnings. When compared to others in the Information Technology sector, the company excelled with a growth rate higher than the average among peers.
Net Margin: The company's net margin is a standout performer, exceeding industry averages. With an impressive net margin of 24.57%, the company showcases strong profitability and effective cost control.
Return on Equity (ROE): The company's ROE is a standout performer, exceeding industry averages. With an impressive ROE of 9.15%, the company showcases effective utilization of equity capital.
Return on Assets (ROA): Applied Mat's ROA surpasses industry standards, highlighting the company's exceptional financial performance. With an impressive 5.09% ROA, the company effectively utilizes its assets for optimal returns.
Debt Management: Applied Mat's debt-to-equity ratio is below the industry average at 0.33, reflecting a lower dependency on debt financing and a more conservative financial approach.
<h2>Analyst Ratings: What Are They?</h2>
Analysts work in banking and financial systems and typically specialize in reporting for stocks or defined sectors. Analysts may attend company conference calls and meetings, research company financial statements, and communicate with insiders to publish "analyst ratings" for stocks. Analysts typically rate each stock once per quarter.
Some analysts publish their predictions for metrics such as growth estimates, earnings, and revenue to provide additional guidance with their ratings. When using analyst ratings, it is important to keep in mind that stock and sector analysts are also human and are only offering their opinions to investors.
Which Stocks Are Analysts Recommending Now?
Benzinga Edge gives you instant access to all major analyst upgrades, downgrades, and price targets. Sort by accuracy, upside potential, and more. <a href="https://www.benzinga.com/premium/ideas/benzinga-edge-checkout/?t=be8be9arja3be22bz21&amp;utm_source=benzinga-insights">Click here to stay ahead of the market</a>.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

AMAT

Deep Dive Into Applied Mat Stock: Analyst Perspectives (18 Ratings)

Beyond Meat's (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BYND#NYSE">BYND</a>) short percent of float has risen 7.22% since its last report. The company recently reported that it has 27.90 million shares sold short, which is 44.68% of all regular shares that are available for trading. Based on its trading volume, it would take traders 7.34 days to cover their short positions on average.
<h3>Why Short Interest Matters</h3>
Short interest is the number of shares that have been sold short but have not yet been covered or closed out. <a href="https://www.benzinga.com/money/how-to-short-a-stock/">Short selling</a> is when a trader sells shares of a company they do not own, with the hope that the price will fall. Traders make money from short selling if the price of the stock falls and they lose if it rises.
Short interest is important to track because it can act as an indicator of market sentiment towards a particular stock. An increase in short interest can signal that investors have become more bearish, while a decrease in short interest can signal they have become more bullish.
See Also: <a href="https://www.benzinga.com/short-interest">List of the most shorted stocks</a>
<h3>Beyond Meat Short Interest Graph (3 Months)</h3>
<img src="https://www.benzinga.com/files/images/story/2024/1732906811_0.png" alt="short_fig" />
As you can see from the chart above the percentage of shares that are sold short for Beyond Meat has grown since its last report. This does not mean that the stock is going to fall in the near-term but traders should be aware that more shares are being shorted.
<h3>Comparing Beyond Meat's Short Interest Against Its Peers</h3>
Peer comparison is a popular technique amongst analysts and investors for gauging how well a company is performing. A company's peer is another company that has similar characteristics to it, such as industry, size, age, and financial structure. You can find a company's peer group by reading its 10-K, proxy filing, or by doing your own similarity analysis.
According to <a href="https://pro.benzinga.com/">Benzinga Pro</a>, Beyond Meat's peer group average for short interest as a percentage of float is 5.51%, which means the company has more short interest than most of its peers.
Did you know that increasing short interest can actually be bullish for a stock? <a href="https://www.benzinga.com/money/how-to-make-money-on-a-short-squeeze/">This post by Benzinga Money explains how you can profit from it.</a>
This article was generated by Benzinga's automated content engine and was reviewed by an editor.

BYND

(BYND) - Analyzing Beyond Meat's Short Interest

Super Micro Computer, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SMCI#NASDAQ">SMCI</a>), Nvidia Corp. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NVDA#NASDAQ">NVDA</a>), MicoStrategy, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MSTR#NASDAQ">MSTR</a>), SoFi Technologies, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SOFI#NASDAQ">SOFI</a>) and Tesla, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TSLA#NASDAQ">TSLA</a>) are the top five trending tickers on Yahoo Finance Friday. Here's a look at what grabbed retail investors' attention as much of Wall Street <a href="https://www.benzinga.com/24/11/42244807/dollar-snaps-8-week-winning-streak-falls-to-1-month-low-versus-yen-as-traders-brace-for-bojs-interest-rate-hike">took the day off. </a>
SMCI: Super Micro shares are dropping Friday as the stock continues its <a href="https://www.benzinga.com/trading-ideas/movers/24/11/42166890/smci-surges-65-in-a-week-but-is-volatility-the-new-normal">rollercoaster of ups</a> and downs. Allegations of financial misconduct at SMCI, the resignation of its auditor and the potential delisting of its stock have caused shares to tumble more than 60% over the past six months. Earlier this week, the company disclosed that <a href="https://www.benzinga.com/markets/equities/24/11/42210660/super-micro-computer-makes-slight-recovery-during-wednesday-pre-market-after-after-ending-loan-agreements-with-major-banks">it had prepaid</a> and ended its loan agreements with Cathay Bank and Bank of America N.A.
Read Next: <a href="https://www.benzinga.com/general/sports/24/11/42246187/tiger-woods-rory-mcilroy-pga-tour-sofi-prep-golf-remixed-for-2025-tgl-launch">Tiger Woods, Rory McIlroy, PGA Tour, SoFi Prep &#8216;Golf Remixed&#8217; For 2025 TGL Launch</a>
NVDA: Traders are hopeful that less<a href="https://www.benzinga.com/24/11/42244387/nvidia-lam-reasearch-applied-materials-stocks-gain-as-biden-government-eyes-softer-semiconductor-sanctions-against-china"> stringent sanctions</a> on semiconductor equipment and AI memory chips are coming, following reports that an announcement could be expected as soon as next week. Nvidia and other semiconductor stocks are up on the news.&nbsp;
MSTR: MicroStrategy's stock looks to be running <a href="https://www.benzinga.com/news/24/11/42240952/microstrategy-shares-jumps-in-friday-pre-market-as-bitcoin-rebounds-to-96000-consensus-price-target-reveals-over-15-upside-for-mstr">out of steam</a> as the trading week draws to an early close on Friday. However, the stock has gained nearly 50% over the past month as the price of Bitcoin climbed to just under the $100,000 mark.&nbsp;
SOFI: SoFi shares are back on the list as this retail investor favorite continues to climb, notching gains of more than 55% over the past month. The company <a href="https://www.benzinga.com/pressreleases/24/11/b41902169/sofis-new-robo-advisor-platform-expands-everyday-investors-access-to-diversified-asset-classes" target="_blank" rel="noopener">recently announced</a> the launch of its Robo-Advisor platform, which leverages a partnership with BlackRock to expose investors to new strategies and funds.  
TSLA: Tesla rounds out the list on Friday, trading higher on relatively light volume. Tesla shares have rebounded more than 90% in the second half of the year as CEO Elon Musk took a prominent role as President-elect Donald Trump's new advisor. It <a href="https://www.benzinga.com/economics/macro-economic-events/24/11/42247850/gm-other-us-automakers-brace-for-sharp-profit-squeeze-from-trump-tariffs-analysts">remains unclear</a> what effect the Trump administration will have on the EV industry and Tesla as a result. 
Read Next: 
<ul>
<li><a href="https://www.benzinga.com/news/retail-sales/24/11/42170721/thanksgiving-dinner-gobbles-up-19-more-cash-this-year-many-holiday-hosts-already-regret-their-decision">Thanksgiving Dinner Gobbles Up 19% More Cash This Year, Many Holiday Hosts &#8216;Already Regret Their Decision&#8217;</a></li>
</ul>
Image:&nbsp;Gerd Altmann from Pixabay

Large Cap

News

Movers

Tech

MSTR

NVDA

SMCI

SOFI

TSLA

Friday's Top 5 Trending Stocks: What's Going On With SMCI, Nvidia, MicroStrategy?

The antitrust case against Steam, initially filed by Wolfire Studios and Dark Catt Studios in 2021, has taken a significant turn.
A U.S. court document <a href="https://www.gamesindustry.biz/wolfire-and-dark-catts-antitrust-lawsuit-against-valve-granted-class-action-status">seen </a>by GamesIndustry.biz, has approved the motion for class certification, broadening the lawsuit's scope to include "any developers, publishers, or individuals" who have adhered to Steam's 30% revenue cut for purchases made since Jan. 28, 2017.
This expansion, granted by United States District Judge Jamal N. Whitehead, amplifies the <a href="https://www.benzinga.com/general/gaming/24/11/41914135/valves-steam-deck-oled-gets-makeover-heres-what-you-need-to-know">stakes for Valve,</a> Steam's parent company, as it faces intensified scrutiny over its business practices.
See Also: <a href="https://www.benzinga.com/news/legal/24/11/42229617/microsofts-xbox-game-store-for-android-ready-to-go-live-says-executive-but-legal-standoff-with-google-halts-launch">Microsoft&#8217;s Xbox Game Store For Android &#8216;Ready To Go Live,&#8217; Says Executive, But Legal Standoff With Google Halts Launch</a>
<h3 class="wp-block-heading">Origins Of Steam&#8217;s Antitrust Case</h3>
The dispute began with Wolfire Games' claim that Valve leverages its dominant market position to impose "an extraordinarily high cut" on sales through its PC platform. The studio argued that this practice exploits both publishers and consumers, stifling competition and inflating prices.
After the original lawsuit was dismissed in November 2021, Wolfire returned in May 2022 with a revised complaint. This time, the focus sharpened on Valve's Platform Most Favoured Nations (PMFN) policy, which allegedly ensures Steam's commission remains "supracompetitive."
<h3 class="wp-block-heading">Allegations And Antitrust Implications</h3>
The plaintiffs contend that Valve's policies harm competition in three critical ways:
<ul>
<li>Steam secures a disproportionately high commission.</li>
<li>Developers and publishers are unable to compete across distribution platforms.</li>
<li>Rival platforms struggle to gain traction in the marketplace.</li>
</ul>
These practices, the lawsuit alleges, violate multiple antitrust laws, including Washington&#8217;s Consumer Protection Act. The plaintiffs are seeking &#8220;class-wide remedies&#8221; to address the financial impact on publishers and inflated costs for consumers.
<h3 class="wp-block-heading">Valve's Defense And Courtroom Developments</h3>
Valve has pushed back against these claims, particularly targeting the testimony of Dr. Steven Schwartz, an expert witness whose findings characterize Valve as the dominant force in PC game distribution. 
Valve argued that Schwartz's conclusions were "based on faulty methods and improper assumptions" and sought to have his testimony dismissed. However, the court rejected this request, allowing Schwartz&#8217;s analysis to remain part of the proceedings.
<h3 class="wp-block-heading">Broader Implications</h3>
With the lawsuit now class-certified, it opens the door for a wider array of developers and publishers to join the case. Wolfire and Dark Catt will act as class representatives, potentially uniting a broad coalition of industry stakeholders under the same legal banner.
This case depicts growing concerns about market dominance in the digital distribution sector. As rival platforms like the Epic Games Store attempt to chip away at Steam's market share, the outcome of this lawsuit could set significant precedents for how revenue-sharing models and platform policies are regulated moving forward.
Read Next:
<ul>
<li><a href="https://www.benzinga.com/general/gaming/24/11/41996480/1-8-million-instances-of-hate-content-on-steam-is-valve-ignoring-extremism-report">1.8 Million Instances Of Hate Content On Steam — Is Valve Ignoring Extremism?: Report</a></li>
</ul>
Image created using photos from Shutterstock.

Gaming

Legal

General

Antitrust Lawsuit Against Steam Expands To Include All Developers Since 2017

Celestica's (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CLS#NYSE">CLS</a>) short percent of float has risen 15.62% since its last report. The company recently reported that it has 3.41 million shares sold short, which is 2.96% of all regular shares that are available for trading. Based on its trading volume, it would take traders 1.29 days to cover their short positions on average.
<h3>Why Short Interest Matters</h3>
Short interest is the number of shares that have been sold short but have not yet been covered or closed out. <a href="https://www.benzinga.com/money/how-to-short-a-stock/">Short selling</a> is when a trader sells shares of a company they do not own, with the hope that the price will fall. Traders make money from short selling if the price of the stock falls and they lose if it rises.
Short interest is important to track because it can act as an indicator of market sentiment towards a particular stock. An increase in short interest can signal that investors have become more bearish, while a decrease in short interest can signal they have become more bullish.
See Also: <a href="https://www.benzinga.com/short-interest">List of the most shorted stocks</a>
<h3>Celestica Short Interest Graph (3 Months)</h3>
<img src="https://www.benzinga.com/files/images/story/2024/1732905923_0.png" alt="short_fig" />
As you can see from the chart above the percentage of shares that are sold short for Celestica has grown since its last report. This does not mean that the stock is going to fall in the near-term but traders should be aware that more shares are being shorted.
<h3>Comparing Celestica's Short Interest Against Its Peers</h3>
Peer comparison is a popular technique amongst analysts and investors for gauging how well a company is performing. A company's peer is another company that has similar characteristics to it, such as industry, size, age, and financial structure. You can find a company's peer group by reading its 10-K, proxy filing, or by doing your own similarity analysis.
According to <a href="https://pro.benzinga.com/">Benzinga Pro</a>, Celestica's peer group average for short interest as a percentage of float is 2.88%, which means the company has more short interest than most of its peers.
Did you know that increasing short interest can actually be bullish for a stock? <a href="https://www.benzinga.com/money/how-to-make-money-on-a-short-squeeze/">This post by Benzinga Money explains how you can profit from it.</a>
This article was generated by Benzinga's automated content engine and was reviewed by an editor.

Peering Into Celestica's Recent Short Interest

JPMorgan Chase's (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/JPM#NYSE">JPM</a>) short percent of float has risen 13.83% since its last report. The company recently reported that it has 30.12 million shares sold short, which is 1.07% of all regular shares that are available for trading. Based on its trading volume, it would take traders 2.77 days to cover their short positions on average.
<h3>Why Short Interest Matters</h3>
Short interest is the number of shares that have been sold short but have not yet been covered or closed out. <a href="https://www.benzinga.com/money/how-to-short-a-stock/">Short selling</a> is when a trader sells shares of a company they do not own, with the hope that the price will fall. Traders make money from short selling if the price of the stock falls and they lose if it rises.
Short interest is important to track because it can act as an indicator of market sentiment towards a particular stock. An increase in short interest can signal that investors have become more bearish, while a decrease in short interest can signal they have become more bullish.
See Also: <a href="https://www.benzinga.com/short-interest">List of the most shorted stocks</a>
<h3>JPMorgan Chase Short Interest Graph (3 Months)</h3>
<img src="https://www.benzinga.com/files/images/story/2024/1732905917_0.png" alt="short_fig" />
As you can see from the chart above the percentage of shares that are sold short for JPMorgan Chase has grown since its last report. This does not mean that the stock is going to fall in the near-term but traders should be aware that more shares are being shorted.
<h3>Comparing JPMorgan Chase's Short Interest Against Its Peers</h3>
Peer comparison is a popular technique amongst analysts and investors for gauging how well a company is performing. A company's peer is another company that has similar characteristics to it, such as industry, size, age, and financial structure. You can find a company's peer group by reading its 10-K, proxy filing, or by doing your own similarity analysis.
According to <a href="https://pro.benzinga.com/">Benzinga Pro</a>, JPMorgan Chase's peer group average for short interest as a percentage of float is 1.09%, which means the company has less short interest than most of its peers.
Did you know that increasing short interest can actually be bullish for a stock? <a href="https://www.benzinga.com/money/how-to-make-money-on-a-short-squeeze/">This post by Benzinga Money explains how you can profit from it.</a>
This article was generated by Benzinga's automated content engine and was reviewed by an editor.

How Is The Market Feeling About JPMorgan Chase?

Teladoc Health's (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/TDOC#NYSE">TDOC</a>) short percent of float has fallen 4.62% since its last report. The company recently reported that it has 25.69 million shares sold short, which is 19.39% of all regular shares that are available for trading. Based on its trading volume, it would take traders 3.79 days to cover their short positions on average.
<h3>Why Short Interest Matters</h3>
Short interest is the number of shares that have been sold short but have not yet been covered or closed out. <a href="https://www.benzinga.com/money/how-to-short-a-stock/">Short selling</a> is when a trader sells shares of a company they do not own, with the hope that the price will fall. Traders make money from short selling if the price of the stock falls and they lose if it rises.
Short interest is important to track because it can act as an indicator of market sentiment towards a particular stock. An increase in short interest can signal that investors have become more bearish, while a decrease in short interest can signal they have become more bullish.
See Also: <a href="https://www.benzinga.com/short-interest">List of the most shorted stocks</a>
<h3>Teladoc Health Short Interest Graph (3 Months)</h3>
<img src="https://www.benzinga.com/files/images/story/2024/1732905912_0.png" alt="short_fig" />
As you can see from the chart above the percentage of shares that are sold short for Teladoc Health has declined since its last report. This does not mean that the stock is going to rise in the near-term but traders should be aware that less shares are being shorted.
<h3>Comparing Teladoc Health's Short Interest Against Its Peers</h3>
Peer comparison is a popular technique amongst analysts and investors for gauging how well a company is performing. A company's peer is another company that has similar characteristics to it, such as industry, size, age, and financial structure. You can find a company's peer group by reading its 10-K, proxy filing, or by doing your own similarity analysis.
According to <a href="https://pro.benzinga.com/">Benzinga Pro</a>, Teladoc Health's peer group average for short interest as a percentage of float is 5.33%, which means the company has more short interest than most of its peers.
Did you know that increasing short interest can actually be bullish for a stock? <a href="https://www.benzinga.com/money/how-to-make-money-on-a-short-squeeze/">This post by Benzinga Money explains how you can profit from it.</a>
This article was generated by Benzinga's automated content engine and was reviewed by an editor.

TDOC

How Is The Market Feeling About Teladoc Health?

Cardano (CRYPTO: <a class="ticker" href="https://www.benzinga.com/quote/ada/usd">ADA</a>) is up 4.5% over the past 24 hours, boosted by <a href="https://www.benzinga.com/trading-ideas/movers/24/11/42237636/bitcoin-ethereum-dogecoin-simmer-down-on-thanksgiving-analyst-sees-significant-shift-from-btc-season-to-alt-season">altcoins enjoying bullish sentiment.</a>
<figure class="wp-block-table"> 
<table>
<tbody>
<tr>
<td>Cryptocurrency</td>
<td>Price&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</td>
<td>Market Cap</td>
<td>24-Hour Trend</td>
<td>7-Day Trend</td>
</tr>
<tr>
<td>Cardano (CRYPTO: <a class="ticker" href="https://www.benzinga.com/quote/ada/usd">ADA</a>)</td>
<td>$1.05</td>
<td>$37.4 billion</td>
<td>+4.5%</td>
<td>+8%</td>
</tr>
<tr>
<td>Algorand (CRYPTO: <a class="ticker" href="https://www.benzinga.com/quote/algo/usd">ALGO</a>)</td>
<td>$0.39</td>
<td>$327 billion</td>
<td>+30%</td>
<td>+62%</td>
</tr>
<tr>
<td>Ripple (CRYPTO: <a class="ticker" href="https://www.benzinga.com/quote/xrp/usd">XRP</a>) </td>
<td>$1.70</td>
<td>$96.6 billion</td>
<td>+15%</td>
<td>+14.5%</td>
</tr>
</tbody>
</table>
</figure>
Trader Notes: Crypto trader Brandon Hong noted in a post on X on Friday that Cardano offered traders an entry of around 80 cents.
From current levels, he anticipates ADA to push higher to $1.20 and, if that level is successfully reclaimed, possibly to $1.60 or further.
Pseudonymous trader Ssebi also <a href="https://x.com/Av_Sebastian/status/1862468049858679094">targets</a> $1.25, while trader Altcoin Scholar sees a chart pattern playing out that could possibly <a href="https://x.com/AltcoinScholar/status/1862210098879504541">take</a> ADA to $2 in the long run.
Community News: Digital asset manager Bitwise on Nov. 27 submitted an <a href="https://www.sec.gov/files/rules/sro/nysearca/2024/34-101775.pdf">application</a> for an exchange-traded fund (ETF) based on its existing 10 Crypto Index Fund.
Cardano holds a weight of 0.70% in the index fund.
Cardano co-founder Charles Hoskinson highlighted a <a href="https://x.com/cardano_whale/status/1861637989983756397">tweet</a> from a community member, showing that Cardano handles one-quarter to one-half of the transactions of Bitcoin (CRYPTO: <a class="ticker" href="https://www.benzinga.com/quote/btc/usd">BTC</a>) and Ethereum (CRYPTO: <a class="ticker" href="https://www.benzinga.com/quote/eth/usd">ETH</a>) while trading at under 10% of their valuation.
The community member pointed out that Cardano is &#8220;one of the most organic chains out there.&#8221;
<figure class="wp-block-embed is-type-rich is-provider-twitter wp-block-embed-twitter"> 
<div class="wp-block-embed__wrapper">
<blockquote class="twitter-tweet" data-width="500" data-dnt="true">Daily transactions, 25 Nov Bitcoin 605k Ethereum 1292k Cardano 322k ADA does 25%-53% the transactions of BTC and ETH at 2%-8% the market cap These are the most organic chains out there, VC chain figures of hugely different magnitude can be considered unreliable or meaningless
&mdash; whale (@cardano_whale) <a href="https://twitter.com/cardano_whale/status/1861637989983756397?ref_src=twsrc%5Etfw">November 27, 2024</a></blockquote>
<script async src="https://platform.twitter.com/widgets.js" charset="utf-8"></script></div>
</figure>
Another notable milestone was when Cardano deployed its first zero-knowledge (ZK) smart contract, Halo2, <a href="https://www.benzinga.com/markets/cryptocurrency/24/11/42221059/cardano-price-surges-above-one-dollar-on-200-30-day-rally-what-is-going-on-with-ada">on its mainnet.</a>
Read Next:&nbsp;
<ul>
<li><a href="https://www.benzinga.com/markets/cryptocurrency/24/11/42244078/vladimir-putin-signs-bitcoin-mining-crypto-taxation-law">Vladimir Putin Signs Bitcoin Mining, Crypto Taxation Law</a></li>
</ul>
Image: Shutterstock

Coverage of Bitcoin, Etherum, Ripple and all the latest digital currencies.

Cryptocurrency

$ADA

$ALGO

$BTC

$ETH

$XRP

ADA Price Up 4.5% In 24 Hours: Why Is Cardano Going Up?

The regional banking sector has spent much of the last two years making headlines for all the wrong reasons. <a href="https://www.fdic.gov/resources/resolutions/bank-failures/in-brief/2023">Bank failures</a> like Silicon Valley, Signature Bank, and First Republic Bank rocked the sector, and the SPDR Regional Banking ETF (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/KRE#NYSE">KRE</a>) dropped more than 40% at the end of 2023.
Investors remained on edge to start 2024 following another pair of failures, but the sector has rebounded following the Federal Reserve's rate-cut strategy and the 2024 U.S. presidential election results.
The incoming Trump administration is expected to replace several top regulators, such as Linda Khan (at the FTC), Rohit Chopra (CFPB), and Gary Gensler (SEC), which could create an atmosphere for more mergers and acquisitions through less stringent regulation.
Regional banks stand to be some of the biggest beneficiaries of this attitude change, and KRE has already jumped 18% in the last month.
Let&#8217;s take a look at five of the most promising regional bank stocks to buy ahead of the new crop of regulators.
<h2 class="wp-block-heading">How We Narrowed It Down to Six Stocks to Buy</h2>
Looser capital guidelines and diminished regulatory scrutiny will benefit plenty of firms in the finance sector. We trimmed our regional bank stock list down to five based on the following criteria:
<ul>
<li>Beneficiary of Relaxed Deregulation &#8211; Several banking rules involving capital requirements (like Basel III) and liquidity standards could be relaxed during a second Trump admin, in addition to a more friendly M&amp;A environment. Regional banks can't meet these requirements as efficiently as larger national banks, so deregulation often benefits smaller banks.</li>
<li>Valuation Metrics &#8211; The banks on our list have affordable stocks compared to their sector peers based on metrics like Price-to-Earnings (P/E), Price-to-Sales (P/S), and Price-to-Book (P/B) rates.</li>
<li>Dividend Yield &#8211; If you own bank stocks, you want to be compensated with stock price appreciation and dividend income. These regional banks all pay higher dividend yields than the industry average.</li>
</ul>
<h2 class="wp-block-heading">Top Six Regional Banks to Buy</h2>
Based on the above criteria, here are five regional bank stocks to consider adding to your portfolio before a second Trump administration, and its new crop of top regulators, sets up shop in Washington.
<h3 class="wp-block-heading">US Bancorp (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/USB#NYSE">USB</a>)</h3>
US Bancorp&#8217;s roots date back to the Civil War when it was awarded the 24th national bank charter of the United States. Today, it&#8217;s one of the largest regional banks in the United States, with a market cap of over $83 billion and 68,000 employees. USB shares have lagged in 2024, with a 23% year-to-date gain compared to 30% from KRE, but looser regulations could be a tailwind as the bank <a href="https://www.usbank.com/about-us-bank/company-blog/article-library/us-bancorp-completes-acquisition-of-union-bank.html">acquired MUFG Union Bank</a> in 2022 to expand operations into California, Oregon, and Washington. The stock has reasonable fundamental metrics like a 16.5 P/E ratio and 1.97 P/S ratio and pays a 3.73% dividend yield.
<figure class="wp-block-image size-large"><img loading="lazy" decoding="async" width="1024" height="395" src="https://editorial-assets.benzinga.com/wp-content/uploads/2024/11/29133051/USB-1024x395.png" alt="" class="wp-image-670667" srcset="https://editorial-assets.benzinga.com/wp-content/uploads/2024/11/29133051/USB-1024x395.png 1024w,https://editorial-assets.benzinga.com/wp-content/uploads/2024/11/29133051/USB-300x116.png 300w,https://editorial-assets.benzinga.com/wp-content/uploads/2024/11/29133051/USB-768x296.png 768w,https://editorial-assets.benzinga.com/wp-content/uploads/2024/11/29133051/USB.png 1364w" sizes="(max-width: 1024px) 100vw, 1024px" /></figure>
<h3 class="wp-block-heading">KeyCorp (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/KEY#NYSE">KEY</a>)</h3>
KeyCorp has a market cap under $20 billion and less reach than bigger regional banks like US Bancorp, but the stock makes our list thanks to a combination of good value, high dividend yield, and potential growth from deregulation. The bank has two segments: Consumer Banking and Commercial Banking, with the commercial wing focused on small and mid-size business services. KeyBanc Capital Markets is the company's M/A wheelhouse, having negotiated more than 500 clients on mergers in the mid-size business space. KEY stock has the highest P/E ratio of banks on our list at 19.4 but rewards shareholders with a 4.17% dividend yield, and its P/B rate is bottom third in the sector at 1.3.
<figure class="wp-block-image size-large"><img loading="lazy" decoding="async" width="1024" height="395" src="https://editorial-assets.benzinga.com/wp-content/uploads/2024/11/29133059/KEY-1024x395.png" alt="" class="wp-image-670668" srcset="https://editorial-assets.benzinga.com/wp-content/uploads/2024/11/29133059/KEY-1024x395.png 1024w,https://editorial-assets.benzinga.com/wp-content/uploads/2024/11/29133059/KEY-300x116.png 300w,https://editorial-assets.benzinga.com/wp-content/uploads/2024/11/29133059/KEY-768x296.png 768w,https://editorial-assets.benzinga.com/wp-content/uploads/2024/11/29133059/KEY.png 1364w" sizes="(max-width: 1024px) 100vw, 1024px" /></figure>
<h3 class="wp-block-heading">Regions Financial Corp (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/RF#NYSE">RF</a>)</h3>
Regions Financial doesn't have a hundred-plus-year history like US Bancorp or KeyCorp, but it does offer a variety of banking and wealth management services to clients across the southern region. RF shares have actually outperformed KRE so far in 2024 (42% vs 30%), and its debt/equity level of 0.35 is the lowest of our selections, indicating a well-capitalized bank poised to benefit from more risk-taking. The stock pays a 3.66% dividend yield with a 13.4 P/E ratio and 1.48 P/B ratio.
<figure class="wp-block-image size-large"><img loading="lazy" decoding="async" width="1024" height="395" src="https://editorial-assets.benzinga.com/wp-content/uploads/2024/11/29133104/RF-1024x395.png" alt="" class="wp-image-670669" srcset="https://editorial-assets.benzinga.com/wp-content/uploads/2024/11/29133104/RF-1024x395.png 1024w,https://editorial-assets.benzinga.com/wp-content/uploads/2024/11/29133104/RF-300x116.png 300w,https://editorial-assets.benzinga.com/wp-content/uploads/2024/11/29133104/RF-768x296.png 768w,https://editorial-assets.benzinga.com/wp-content/uploads/2024/11/29133104/RF.png 1364w" sizes="(max-width: 1024px) 100vw, 1024px" /></figure>
<h3 class="wp-block-heading">Truist Financial Corp (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/TFC#NYSE">TFC</a>)</h3>
Formed during the merger of SunTrust Bank and BB&amp;T Corp, Truist Financial is the second-largest regional bank on our list, and one of the reasons is that KRE is up more than 30% this year. TFC shares have matched the regional banking ETF performance almost penny for penny in 2024, but the stock remains well below its 2022 all-time high. Truist has the lowest P/B ratio on our list at 1.08, pays a 4.36% dividend yield, and recently sold off its insurance and asset management subsidiaries to improve its liquidity and capitalization situation. Truist mainly serves states east of the Mississippi River but plans to expand operations in the Sun Belt. These plans could benefit from increased M/A activity and deregulation in the next few years.
<a href="https://www.benzinga.com/premium/ideas/matt-options-inner-circle-checkout-black-friday/?utm_source=WebRD-1129">BLACK FRIDAY: Don&#8217;t Miss Out on Big Gains With Matt Maley &#8211; $1000 Off</a>
<figure class="wp-block-image size-large"><img loading="lazy" decoding="async" width="1024" height="395" src="https://editorial-assets.benzinga.com/wp-content/uploads/2024/11/29133110/TFC-1024x395.png" alt="" class="wp-image-670670" srcset="https://editorial-assets.benzinga.com/wp-content/uploads/2024/11/29133110/TFC-1024x395.png 1024w,https://editorial-assets.benzinga.com/wp-content/uploads/2024/11/29133110/TFC-300x116.png 300w,https://editorial-assets.benzinga.com/wp-content/uploads/2024/11/29133110/TFC-768x296.png 768w,https://editorial-assets.benzinga.com/wp-content/uploads/2024/11/29133110/TFC.png 1364w" sizes="(max-width: 1024px) 100vw, 1024px" /></figure>
<h3 class="wp-block-heading">M&amp;T Bank (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/MTB#NYSE">MTB</a>)</h3>
M&amp;T Bank (which stands for Manufacturers and Traders) is one of the nation&#8217;s oldest banks, with predecessors tracing back as far as 1856. MTB has a $36 billion market cap and pays a 2.45% dividend, the lowest on our list but easily sustained by the company's income. The stock has been one of 2024's biggest success stories, posting an astonishing 60% gain in 2024, which doubled the regional banking ETF. Following the bank's strong October earnings report, more gains could be on the horizon, causing many analysts to upgrade their ratings and price targets. M&amp;T Bank has a 16.3 P/E ratio and a 1.4 P/B ratio, and its net profit margin of 18.7 is bested only by Regions Financial.
<figure class="wp-block-image size-large"><img loading="lazy" decoding="async" width="1024" height="395" src="https://editorial-assets.benzinga.com/wp-content/uploads/2024/11/29133115/MTB-1024x395.png" alt="" class="wp-image-670671" srcset="https://editorial-assets.benzinga.com/wp-content/uploads/2024/11/29133115/MTB-1024x395.png 1024w,https://editorial-assets.benzinga.com/wp-content/uploads/2024/11/29133115/MTB-300x116.png 300w,https://editorial-assets.benzinga.com/wp-content/uploads/2024/11/29133115/MTB-768x296.png 768w,https://editorial-assets.benzinga.com/wp-content/uploads/2024/11/29133115/MTB.png 1364w" sizes="(max-width: 1024px) 100vw, 1024px" /></figure>
<h3 class="wp-block-heading">Discover Financial (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/DFS#NYSE">DFS</a>)&nbsp;</h3>
Discover Financial has been linked with Capital One since the latter announced intentions to purchase the former for $35 billion in February. However, the deal has been in limbo since New York regulators began investigating the acquisition for possible antitrust violations. DFS shares traded in a tight range from July until the week of the election, but both DFS and COF stocks immediately gapped up on the Wednesday following Trump's victory. Investors anticipate the deal going through in a less harsh regulatory environment, so DFS shares could continue to rally in the weeks ahead.
<figure class="wp-block-image size-large"><img loading="lazy" decoding="async" width="1024" height="395" src="https://editorial-assets.benzinga.com/wp-content/uploads/2024/11/29133121/DFS-1024x395.png" alt="" class="wp-image-670672" srcset="https://editorial-assets.benzinga.com/wp-content/uploads/2024/11/29133121/DFS-1024x395.png 1024w,https://editorial-assets.benzinga.com/wp-content/uploads/2024/11/29133121/DFS-300x116.png 300w,https://editorial-assets.benzinga.com/wp-content/uploads/2024/11/29133121/DFS-768x296.png 768w,https://editorial-assets.benzinga.com/wp-content/uploads/2024/11/29133121/DFS.png 1364w" sizes="(max-width: 1024px) 100vw, 1024px" /></figure>
Keep in mind that campaign promises don't always materialize in reality, and the previous Trump administration was often as much bark as bite. Less regulation and more M&amp;A are expected, but investments based on political overtures are short-term bets by nature. Don't hang on to losing stocks if the regulatory environment we get is different than anticipated.
In 2024, Matt Maley's members had the chance to make 570% on TLT in 24 hours, 460% on GDX in a week, and even see five winning trades in one day. This Black Friday, save $1000 and trade alongside a Wall Street legend with real-time alerts and proven strategies. <a href="https://www.benzinga.com/premium/ideas/matt-options-inner-circle-checkout-black-friday/?utm_source=WebRD-1129">Click here to get started.</a>
Image via Midjourney

Opinion

6 Regional Bank Stocks to Buy Before Trump Names New SEC Leadership

CorVel Corporation (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CRVL#NASDAQ">CRVL</a>) announces V. Gordon Clemons is electing to retire as a member of the Company's Board of Directors (the "Board") and as Chairman of the Board, effective November 26, 2024, after 37 years of service. Clemons founded CorVel Corporation in 1988 and has served as Chairman of the Board since the Company went public in 1991. Effective upon Clemons' retirement, Michael G. Combs, the Company's President and Chief Executive Officer, was appointed as the new Chairman of the Board. Clemons has been an advisor to Combs since 2017, and he will continue to be available to Combs as an outside consultant.

Management

CRVL

CorVel Announces Retirement Of V. Gordon Clemons As Chairman Of The Board, Effective November 26, 2024; President And CEO, Michael G. Combs Was Appointed As The New Chairman Of The Board

Retailer Target Corporation (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/TGT#NYSE">TGT</a>) could enjoy a boost for the holiday shopping season thanks to the likes of Pokémon and Taylor Swift, according to early <a href="https://www.benzinga.com/topic/black-friday">Black Friday consumer data.</a>
What Happened: Experts expect Black Friday sales <a href="https://www.benzinga.com/news/24/11/42236796/black-friday-cyber-monday-shopping-set-to-break-sales-records">to top records,</a> which could be good news for retailers like Target Corporation.
Early Black Friday data for Target's website could also be good news for The Pokémon Company, which is partially owned by Nintendo Co (OTC:<a class="ticker" href="https://www.benzinga.com/stock/NTDOY#OTC">NTDOY</a>).
Pokémon is one of the top searched items by shoppers on Target&#8217;s website Friday, according to data from <a href="https://www.similarweb.com/">Similarweb</a>.
Here are the top 10 searched items on Target for Black Friday:
<ol>
<li>Pokémon</li>
<li>Pokémon cards</li>
<li>Lego</li>
<li>Airpods</li>
<li>Nintendo Switch</li>
<li>Apple Watch</li>
<li>iPad</li>
<li>Taylor Swift book</li>
<li>Prismatic Evolutions Pokémon</li>
<li>Christmas tree</li>
</ol>
Pokémon dominates Target&#8217;s top-searched items list with three items, matching Apple, which also has three items on the list (Airpods, Apple Watch, iPad).
The items from Pokémon rank first, second and ninth, making the company the most dominant among Target shoppers.
An exclusive Taylor Swift <a href="https://www.benzinga.com/general/entertainment/24/10/41338328/taylor-swift-teams-up-with-target-for-exclusive-black-friday-merch-will-swifties-boost-q4-s">book with photos</a> and stories from her record-breaking Eras Tour was a top-searched item online for Black Friday shoppers. The book is exclusive to Target and will be available in stores on Friday before a wider release on Target&#8217;s website in the coming days.
<a href="https://www.benzinga.com/economics/macro-economic-events/24/11/42244324/black-friday-frenzy-shoppers-queue-for-taylor-swift-merch-retro-gadgets-and-more-as-retailers-open-doors-early-amid-shortened-shopping-season">Reports of lines</a> outside Target stories Friday showed the continued power of Swift fans as many shoppers have turned to online shopping over waiting outside stores on Black Friday. 
Read Also: <a href="https://www.benzinga.com/24/11/42247063/apple-products-dominate-early-black-friday-trending-searches">Apple Products Dominate Early Black Friday Trending Searches</a>
Why It's Important: For more than 25 years, Pokémon has been one of the top brands for kids in sectors such as video games, consumer products, and trading cards.
For shoppers at Target, Pokémon cards dominate the list, including the newest set, Prismatic Evolutions, which will be released in January.
This year's holiday shopping season is shorter than normal, with 27 days from the day before Thanksgiving until Christmas Day.
Early shopping searches and data could show which items are most in demand for the holiday season.
Similarweb data that tracked Target along with Amazon, Walmart and Best Buy showed Pokémon cards as the 10th most-searched item on Black Friday overall.
TGT Price Action: Target stock was up 1.6% to $132.31 on Friday versus a 52-week trading range of $120.21 to $181.86. Target stock is down 8% year-to-date.
Read Next: 
<ul>
<li><a href="https://www.benzinga.com/news/24/11/42247827/one-low-tech-toy-blows-away-black-friday-shopping-competition">One Low-Tech Toy Blows Away Black Friday Shopping Competition</a></li>
</ul>
Image created using artificial intelligence via Midjourney.

NTDOY

Target Black Friday Deals: Pokémon Shoppers Gotta Catch 'Em All

By <a href="https://elplanteo.com/author/hernan-panessi/">Hernán Panessi</a> <a href="https://twitter.com/hernanpanessi" target="_blank" rel="noreferrer noopener"></a>via <a href="https://elplanteo.com/yamandu-presidente-cannabis-uruguay/">El Planteo</a>
More than 10 years have passed since <a href="https://elplanteo.com/noticias/latinoamerica/uruguay/">Uruguay</a> became the first country to legalize <a href="https://www.benzinga.com/cannabis">adult-use cannabis</a>. In 2012, then-President <a href="https://elplanteo.com/pepe-mujica-diario-che-guevara/">José "Pepe" Mujica</a> boldly stated, "Someone has to be first," during debates over legalizing cannabis. By December 2013, Uruguay had made history as the world's first nation to legalize cannabis cultivation and sales.
While groundbreaking, Law 19.172 has faced its share of challenges. After years of controversies, irregularities and debates—largely tied to the outgoing administration—the return of the Frente Amplio, a progressive coalition that spearheaded the original law, could usher in renewed approaches to cannabis regulation.
<h3 class="wp-block-heading">A Changing Political Landscape</h3>
With Uruguay's new political configuration, pressing questions arise: What's next for cannabis policy? Will the Frente Amplio prioritize cannabis reform? What stance will newly elected President <a href="https://elplanteo.com/yamandu-presidente-cannabis-uruguay/">Yamandú Orsi</a> take?
Journalist Camilo Salvetti explained to <a href="https://elplanteo.com/">El Planteo</a> that former President Luis Lacalle Pou adopted a "business-oriented approach to cannabis." According to data from the Institute for Regulation and Control of Cannabis (IRCCA), Uruguay currently has:
<ul>
<li>3 licenses for adult-use psychoactive cannabis cultivation,</li>
<li>15 licenses for medical cannabis cultivation,</li>
<li>40 registered pharmacies selling cannabis,</li>
<li>71,843 registered buyers,</li>
<li>11,708 home growers,</li>
<li>410 cannabis clubs, and</li>
<li>13,687 cannabis club members.</li>
</ul>
Salvetti explained, "There are three ways to access cannabis in Uruguay: buying at pharmacies, joining a cannabis club, or registering as a home grower with limits on plant numbers."
Currently, three companies hold licenses to grow, produce and distribute cannabis sold in pharmacies. However, Salvetti noted that government-supplied cannabis often fell short in quality: "The joke is that this marijuana doesn't even get you high." Following complaints from producers, the government increased the allowable THC levels in pharmacy-sold cannabis.
See also: <a href="https://www.benzinga.com/government/regulations/24/11/41996451/uruguays-cannabis-industry-struggles-amid-export-barriers-price-drops">Uruguay&#8217;s Cannabis Industry Struggles Amid Export Barriers, Price Drops</a>
This created friction between cannabis clubs and licensed producers. Salvetti explained, "Producers argued that clubs were not properly regulated, creating a gray market. While more users may be registered at pharmacies, cannabis clubs appear to dominate actual purchases and cash flow."
<h3 class="wp-block-heading">Rethinking Criminalization And Policy</h3>
Under Lacalle Pou's government, prison sentences for minor cannabis trafficking offenses increased, with harsher penalties for "minimal quantities" of cannabis. Salvetti criticized this trend: "The new government must rethink its marijuana policy—whether it serves companies growing state-sanctioned cannabis or focuses on the people."
Activist and educator Rosina Yemini, founder of Cultivando Clubes, noted significant changes after Uruguay's right-wing government came to power in 2020. These shifts primarily affected how cannabis users were judged, leading to increased criminalization and legal ambiguities. Yemini stated, "We now have a large number of home growers in prison."
She expressed hope that President Orsi's government would address these issues and embrace activism in drafting new regulations. Yemini emphasized the importance of engaging IRCCA in open dialogues with advocates.
<h3 class="wp-block-heading">A Politically Stable Cannabis Consensus</h3>
Uruguay's cannabis regulation enjoys broad political support. Across the spectrum, there are no major proposals to reverse legalization. Diego Olivera, a Frente Amplio senator, former head of IRCCA, and national drug policy coordinator, remarked: &#8220;Today, cannabis is a state policy embedded in public policy and societal reality.&#8221;
Olivera observed, "As a socially progressive country, Uruguay sees cannabis regulation as an extension of its individual freedom and state responsibility traditions."
Despite this stability, Olivera acknowledged challenges. For example, early government attempts sought to expand police involvement in cannabis market oversight at the expense of IRCCA. He said, &#8220;That would have marked a return to criminalization, but both the left and center-right opposed it. Instead, regulatory policy remained largely unchanged.&#8221;
While there was some bureaucratic streamlining to boost medical cannabis exports, no major structural reforms occurred under Lacalle Pou's administration.
<h3 class="wp-block-heading">What's Next Under Frente Amplio?</h3>
The Frente Amplio's platform includes proposals to deepen cannabis regulation, including:
<ul>
<li>Promoting cannabis tourism to attract investments,</li>
<li>Revising penalties for minor trafficking offenses,</li>
<li>Expanding membership access to cannabis clubs,</li>
<li>Addressing hurdles in legal cannabis procurement,</li>
<li>Balancing supply with growing demand, and</li>
<li>Strengthening the National Drug Secretariat to improve access and implement harm-reduction policies.</li>
</ul>
Diego Olivera concluded, "The challenge for Frente Amplio is ensuring all cannabis users can access legal avenues."
Cover image: Photo by Marcelo Cúneo, <a href="https://creativecommons.org/licenses/by-sa/4.0">CC BY-SA 4.0</a>, via Wikimedia Commons, edited by El Planteo
This article is from an external unpaid contributor. It does not represent Benzinga&#8217;s reporting and has not been edited for content or accuracy.

Cannabis

Latin America

Interview

10+ Years Of Legal Weed In Uruguay: Will The New Government Expand Access?

<a href="https://investorplace.com">InvestorPlace - Stock Market News, Stock Advice &amp; Trading Tips</a>
Nexalin Technology&nbsp;(NASDAQ:<a href="https://investorplace.com/stock-quotes/nxl-stock-quote/">NXL</a>) stock is down on Friday after the medical device company <a href="https://www.nasdaq.com/press-release/nexalin-technology-announces-pricing-52-million-public-offering-2024-06-27">priced a public offering</a> of its shares.



Nexalin Technology is selling 3 million shares of NXL stock for $1.75 each in this public offering. This has the company expecting gross proceeds from the offering to come in at $5.25 million.



Nexalin Technology notes that Maxim Group LLC is acting as the sole placement agent for the offering. The company is also expecting this offering to close on Monday.



<h2>What This Means for NXL Stock</h2>



With this public offering comes an increase in the total number of outstanding shares of NXL stock. This will also dilute the stakes of current investors in the company. That&rsquo;s one of the reasons why Nexalin Technology is seeing its share price fall today.



In addition to that, the price of the shares in the offering is a significant discount over its prior closing price. The company&rsquo;s shares closed out Thursday at $2.96 per share. It makes sense that shares of NXL shares would drop when the shares in the offering are being sold at such a lower price.



NXL stock is down 35.1% as of Friday morning. This comes with more than 955,000 shares traded. The company&rsquo;s daily average trading volume is closer to 2.9 million shares.



We have more of the latest stock market stories ready to go today!



Our coverage includes all of the hottest stock market news for Friday! A few examples include what&rsquo;s happening with shares of Cosmos Health&nbsp;(NASDAQ:<a href="https://investorplace.com/stock-quotes/cosm-stock-quote/">COSM</a>) and African Agriculture&nbsp;(NASDAQ:<a href="https://investorplace.com/stock-quotes/aagr-stock-quote/">AAGR</a>) stock, as well as the biggest pre-market stock movers this morning. All of that news is available at the following links!



<h2>More Friday Stock Market News</h2>



<ul><li><a href="https://investorplace.com/2024/06/why-is-cosmos-health-cosm-stock-up-65-today/">Why Is Cosmos Health (COSM) Stock Up 65% Today?</a></li>



<li><a href="https://investorplace.com/2024/06/why-is-african-agriculture-aagr-stock-up-55-today/">Why Is African Agriculture (AAGR) Stock Up 55% Today?</a></li>



<li><a href="https://investorplace.com/2024/06/todays-biggest-pre-market-stock-movers-10-top-gainers-and-losers-on-friday-june-28th/">Today&rsquo;s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on&nbsp;Friday</a></li>
</ul>On Penny Stocks and Low-Volume Stocks:&#8239;With only the rarest exceptions, InvestorPlace does not publish commentary about companies that have a market cap of less than $100 million or trade less than 100,000 shares each day. That&rsquo;s because these &ldquo;penny stocks&rdquo; are frequently the playground for scam artists and market manipulators. If we ever do publish commentary on a low-volume stock that may be affected by our commentary, we demand that&#8239;InvestorPlace.com&rsquo;s writers disclose this fact and warn readers of the risks.



Read More:&#8239;Penny Stocks &mdash;&nbsp;<a href="https://investorplace.com/2014/05/fraud-penny-stocks-scams/" target="_blank">How to Profit Without Getting Scammed</a>



On the date of publication, William White did not have (either directly or indirectly) any positions in the securities mentioned in this article. The opinions expressed in this article are those of the writer, subject to the&nbsp;InvestorPlace.com&nbsp;<a href="https://investorplace.com/corporate/investorplace-publishing-guidelines/" target="_blank">Publishing Guidelines</a>.
<h3>More From InvestorPlace</h3>
		<ul><li>
						<a href="https://investorplace.com/2023/10/no-1-ai-investment-might-be-this-company-youve-never-heard-of/?cid=MKT764787&amp;eid=MKT802110">The #1 AI Investment Might Be This Company You&rsquo;ve Never Heard Of</a>
					</li>
																<li>
						<a href="https://investorplace.com/2023/07/elon-musks-project-omega-stuns-silicon-valley-insiders/?cid=MKT738510&amp;eid=MKT766411">Musk&rsquo;s &ldquo;Project Omega&rdquo; May Be Set to Mint New Millionaires. Here&rsquo;s How to Get In.</a>
					</li>
																<li>
						<a href="https://investorplace.com/2024/04/legendary-investor-predicts-forget-a-i-this-technology-is-the-future/?cid=MKT794457&amp;eid=MKT802109">Legendary Investor Predicts: &ldquo;Forget A.I. THIS Technology Is the Future&rdquo;</a>
					</li>
									</ul><div>
			<div></div>
						<div></div>
					</div>
	The post <a href="https://investorplace.com/2024/06/why-is-nexalin-technology-nxl-stock-down-35-today/">Why Is Nexalin Technology (NXL) Stock Down 35% Today?</a> appeared first on <a href="https://investorplace.com">InvestorPlace</a>.

Why Is Nexalin Technology (NXL) Stock Down 35% Today?

<a href="https://investorplace.com">InvestorPlace - Stock Market News, Stock Advice &amp; Trading Tips</a>
Elicio Therapeutics&nbsp;(NASDAQ:<a href="https://investorplace.com/stock-quotes/eltx-stock-quote/">ELTX</a>) stock is falling on Friday after the clinical-stage biotechnology company <a href="https://www.nasdaq.com/press-release/elicio-therapeutics-announces-proposed-public-offering-2024-06-27">announced a proposed public offering</a>.



Elicio Therapeutics has announced its plans for a public offering that will include shares of ELTX stock, warrants to purchase additional shares and pre-funded warrants. What the company doesn&rsquo;t reveal is the size and pricing of the offering.



Elicio Therapeutics says that it intends to use the funds from the offering for &ldquo;the advancement of its development pipeline.&rdquo; It will also use the money for working capital and general corporate purposes.



<h2>What This Means for ELTX Stock</h2>



With this public offering will come an increase in the total number of ELTX shares outstanding. That will also result in the stakes of current investors in Elicio Therapeutics being diluted. That helps explain why shares of ELTX stock are falling on Friday.



To go along with that, investors are likely wary about the pricing of the offering. While it hasn&rsquo;t been announced yet, it&rsquo;s likely to be below the current price of the company&rsquo;s stock. This will likely result in further drops for ELTX shares once the price is announced.



ELTX stock is down 36.2% as of Friday morning. That comes with 18,000 shares traded, as compared to a daily average of about 46,000 shares.



We have more of the most recent stock market stories worth reading about on Friday!



Our coverage includes all of the hottest market news traders need to know about today! That includes everything happening with shares of Nexalin Technology&nbsp;(NASDAQ:<a href="https://investorplace.com/stock-quotes/nxl-stock-quote/">NXL</a>) stock, Cosmos Health&nbsp;(NASDAQ:<a href="https://investorplace.com/stock-quotes/cosm-stock-quote/">COSM</a>) stock and African Agriculture&nbsp;(NASDAQ:<a href="https://investorplace.com/stock-quotes/aagr-stock-quote/">AAGR</a>) stock this morning. You can catch up on all of these matters by checking out the links below!



<h2>More Stock Market News for Friday</h2>



<ul><li><a href="https://investorplace.com/2024/06/why-is-nexalin-technology-nxl-stock-down-35-today/">Why Is Nexalin Technology (NXL) Stock Down 35% Today?</a></li>



<li><a href="https://investorplace.com/2024/06/why-is-cosmos-health-cosm-stock-up-65-today/">Why Is Cosmos Health (COSM) Stock Up 65% Today?</a></li>



<li><a href="https://investorplace.com/2024/06/why-is-african-agriculture-aagr-stock-up-55-today/">Why Is African Agriculture (AAGR) Stock Up 55% Today?</a></li>
</ul>On Penny Stocks and Low-Volume Stocks:&#8239;With only the rarest exceptions, InvestorPlace does not publish commentary about companies that have a market cap of less than $100 million or trade less than 100,000 shares each day. That&rsquo;s because these &ldquo;penny stocks&rdquo; are frequently the playground for scam artists and market manipulators. If we ever do publish commentary on a low-volume stock that may be affected by our commentary, we demand that&#8239;InvestorPlace.com&rsquo;s writers disclose this fact and warn readers of the risks.



Read More:&#8239;Penny Stocks &mdash;&nbsp;<a href="https://investorplace.com/2014/05/fraud-penny-stocks-scams/" target="_blank">How to Profit Without Getting Scammed</a>



On the date of publication, William White did not have (either directly or indirectly) any positions in the securities mentioned in this article. The opinions expressed in this article are those of the writer, subject to the&nbsp;InvestorPlace.com&nbsp;<a href="https://investorplace.com/corporate/investorplace-publishing-guidelines/" target="_blank">Publishing Guidelines</a>.
<h3>More From InvestorPlace</h3>
		<ul><li>
						<a href="https://investorplace.com/2023/10/no-1-ai-investment-might-be-this-company-youve-never-heard-of/?cid=MKT764787&amp;eid=MKT802110">The #1 AI Investment Might Be This Company You&rsquo;ve Never Heard Of</a>
					</li>
																<li>
						<a href="https://investorplace.com/2023/07/elon-musks-project-omega-stuns-silicon-valley-insiders/?cid=MKT738510&amp;eid=MKT766411">Musk&rsquo;s &ldquo;Project Omega&rdquo; May Be Set to Mint New Millionaires. Here&rsquo;s How to Get In.</a>
					</li>
																<li>
						<a href="https://investorplace.com/2024/04/legendary-investor-predicts-forget-a-i-this-technology-is-the-future/?cid=MKT794457&amp;eid=MKT802109">Legendary Investor Predicts: &ldquo;Forget A.I. THIS Technology Is the Future&rdquo;</a>
					</li>
									</ul><div>
			<div></div>
						<div></div>
					</div>
	The post <a href="https://investorplace.com/2024/06/why-is-elicio-therapeutics-eltx-stock-down-36-today/">Why Is Elicio Therapeutics (ELTX) Stock Down 36% Today?</a> appeared first on <a href="https://investorplace.com">InvestorPlace</a>.

Why Is Elicio Therapeutics (ELTX) Stock Down 36% Today?

<a href="https://investorplace.com">InvestorPlace - Stock Market News, Stock Advice &amp; Trading Tips</a>
<a href="https://investorplace.com/stock-types/penny-stocks/">Penny stocks</a> are risky and are known for crashing and burning fast. Most of these stocks are unstable and attract a lot of speculations and shifts in the market.&nbsp;



But for those who don&rsquo;t mind the risk, there are some great gems among thousands of subpar penny stocks to buy that can be a strategic investment strategy.&nbsp;



These three penny stocks have performed tremendously in the past couple of weeks and, for keen analysts, are poised to outperform market expectations. The performance of these penny stocks is favored by the prevailing market, political, technological and economic conditions that guarantee their upward movement in the foreseeable future.&nbsp;



Now, let&rsquo;s cover why these are the smartest penny stocks to buy right now, what industry trends prop them and what Wall Street analysts think of their future performance.&nbsp;



<h2>VAALCO Energy (EGY)</h2>



<div><img width="300" height="169" src="https://investorplace.com/wp-content/uploads/2022/03/vet_vermilion_energy_rig_1600-300x169.png" alt="Offshore oil rig near Harlingen, Nederlande. Oil producing is a major economic factor in the Netherlands."><div>Source: travelview / Shutterstock.com</div></div>VAALCO Energy (NYSE:<a href="https://investorplace.com/stock-quotes/egy-stock-quote/">EGY</a>)&nbsp; is a fast-rising Texas-based oil and gas company operating in <a href="https://www.vaalco.com/">West and North Africa</a> and parts of North America. The company has seen tremendous growth over the last couple of years as <a href="https://www.imf.org/en/Blogs/Articles/2022/03/15/blog-how-war-in-ukraine-is-reverberating-across-worlds-regions-031522">Russia-Ukraine war triggered a global oil supply shortage</a> and a sharp demand incline.&nbsp;<a href="https://investorplace.com/cryptocurrency//"></a>



The company has ramped up its production since 2022, witnessing a YOY growth of <a href="https://www.usatoday.com/money/blueprint/investing/best-penny-stocks/#:~:text=VAALCO%20Energy%20(EGY).,Savara%20(SVRA).">20%</a> in 2023 and reporting a revenue jump of 25% in its most recent quarterly earnings report. With a current yield of about 3.99% and its <a href="https://www.nasdaq.com/market-activity/stocks/egy/revenue-eps">earnings per sharing</a> topping at seven cents per share in 2024 from two cents in 2022, VAALCO Energy proves to be one of the best penny stocks to buy right now.&nbsp;



Although it has recently graduated from a penny stock by surpassing $5, it is quite an affordable deal to ignore. And with almost three Waltsreet analysts offering a 12-month average price forecast of <a href="https://www.tipranks.com/stocks/egy/forecast">$8.92</a>, you should consider placing your money on this one.&nbsp;



VAALCO Energy is set to thrive, with the prevailing geopolitical conditions seeing a shift from Russian oil to Western-produced energy, the company has a real potential to thrive. 



The recent <a href="https://www.vaalco.com/investors/news-events/press-releases/detail/387/vaalco-energy-inc-announces-accretive-all-cash">acquisition of Svenska Petroleum Exploration</a> has also seen an increase in the company&rsquo;s production capacity, and ability to meet the increasing demand for Westen energy.&nbsp;



<h2>SoundHound AI (SOUN)&nbsp;</h2>



<div><img width="300" height="169" src="https://investorplace.com/wp-content/uploads/2024/03/soun1600-3-300x169.png" alt="Person holding smartphone with webpage of US audio recognition company SoundHound Inc. (SOUN) on screen in front of logo. Focus on center of phone display. Unmodified photo."><div>Source: T. Schneider / Shutterstock.com</div></div>SoundHound AI, Inc (NASDAQ:<a href="https://investorplace.com/stock-quotes/soun-stock-quote/">SOUN</a>) is an AI-enabled voice and speech recognition company investing in providing personalized customer experience across all industries. The company provides an AI-powered technology that trains in natural language, understanding which enables companies to utilize the existing data, as well as automate personalized responses to customers.&nbsp;



Sound Hound&rsquo;s penny stocks have been one of the hottest in the market for the past year, surging over 89% YTD. The company has also seen an astounding Q1 sales revenue increase of over <a href="https://seekingalpha.com/news/4104306-soundhound-q1-revenue-surges-as-top-boss-says-voice-ai-fast-becoming-must-have-tool">73%</a>, hitting a record 11.9 million, surpassing market estimates by $1.49 million.&nbsp;



With the company&rsquo;s shares now trading just under $4, the projected tech trends favor tremendous growth and expansion of its operations. With AI titans such as Nvidia (NASDAQ:<a href="https://investorplace.com/cryptocurrency/nvda/">NVDA</a>) throwing their weight behind the company and almost all industries accepting AI to improve customer service, SoundHound AI has a real potential to grow.&nbsp;



<h2>NeXalin Technology, Inc (NXL)</h2>



<div><img width="300" height="169" src="https://investorplace.com/wp-content/uploads/2022/10/pill-bottle-biopharma-biotech-1600-300x169.jpg" alt="Brown glass pill bottle on its side showing white pills inside, with other pill bottles behind it representing MACK stock."><div>Source: shutterstock.com/Champhei</div></div>NeXalin Technology, Inc (NASDAQ:<a href="https://investorplace.com/stock-quotes/nxl-stock-quote/">NXL</a>) is a fast-rising pharmaceutical technology company investing in technologies to treat mental health conditions. The company&rsquo;s transcranial alternating current stimulation technology utilizes a non-invasive treatment method that uses a patented frequency waveform to stimulate a positive response in the patient&rsquo;s brain.



The company has witnessed tremendous growth since this new technology was approved by the FDA. While NeXalin&rsquo;s stock trades at just above $2, it is the most bullish penny stock to buy right now.&nbsp;



Recently, it secured a patent for <a href="https://www.medicaldevice-network.com/news/nexalin-patent-alzheimers-device/">Alzheimer&rsquo;s deep-brain stimulation device</a>, a non-invasion treatment procedure that will revolutionize the treatment of Alzheimer&rsquo;s disease. While the announcement came with an almost 50% surge in the company&rsquo;s stock prices, the company has the potential to grow, having developed a strategic lead in the non-invasive brain treatment technology. NeXalin is definitely one of the most promising penny stocks to buy this year.



On the date of publication, Joel Lim did not have (either directly or indirectly) any positions in the securities mentioned in this article. The opinions expressed in this article are those of the writer, subject to the&nbsp;InvestorPlace.com&nbsp;<a href="https://investorplace.com/corporate/investorplace-publishing-guidelines/" target="_blank">Publishing Guidelines</a>.
<div>Joel Lim is a contributor at InvestorPlace.com and a finance content contractor who creates content for several companies like LTSE and Realtor, along with financial publications, including Business Insider, Yahoo Finance, Mises Institution and Foundation for Economic Education.</div><h3>More From InvestorPlace</h3>
		<ul><li>
						<a href="https://investorplace.com/2023/10/no-1-ai-investment-might-be-this-company-youve-never-heard-of/?cid=MKT764787&amp;eid=MKT802110">The #1 AI Investment Might Be This Company You&rsquo;ve Never Heard Of</a>
					</li>
																<li>
						<a href="https://investorplace.com/2023/07/elon-musks-project-omega-stuns-silicon-valley-insiders/?cid=MKT738510&amp;eid=MKT766411">Musk&rsquo;s &ldquo;Project Omega&rdquo; May Be Set to Mint New Millionaires. Here&rsquo;s How to Get In.</a>
					</li>
																<li>
						<a href="https://investorplace.com/2024/04/legendary-investor-predicts-forget-a-i-this-technology-is-the-future/?cid=MKT794457&amp;eid=MKT802109">Legendary Investor Predicts: &ldquo;Forget A.I. THIS Technology Is the Future&rdquo;</a>
					</li>
									</ul><div>
			<div></div>
						<div></div>
					</div>
	
The post <a href="https://investorplace.com/2024/07/the-3-smartest-penny-stocks-to-buy-with-your-money-right-now/">The 3 Smartest Penny Stocks to Buy With Your Money Right Now</a> appeared first on <a href="https://investorplace.com">InvestorPlace</a>.

The 3 Smartest Penny Stocks to Buy With Your Money Right Now

Nexalin Technology, Inc. (NXL) just unveiled an update. Michael Nketiah will step down as Nexalin Technology Inc.'s Senior Vice President of Clinic...

Nexalin Technology SVP Michael Nketiah Announces Resignation

Nexalin Technology, Inc. ( ($NXL) ) has issued an announcement. Nexalin Technology, Inc. has appointed Carolyn Shelton as their new Senior Vice Pre...

Nexalin Technology Welcomes New SVP Carolyn Shelton

Nexalin Technology (NXL) announced plans to commence a new clinical trial in collaboration with the University of California, San Diego. Dr Ming Xi...

Nexalin announced planned clinical trial utilizing Gen-3 Halo headset

Nexalin Technology (NXL) announced that the Company received notice from The Nasdaq Stock Market on October 31, 2024, notifying the Company that it...

Nexalin Technology regains compliance with Nasdaq continued listing rules

Nexalin Technology, Inc. (NXL) has disclosed a new risk, in the Debt & Financing category. Nexalin Technology, Inc. currently faces no defaults upo...

Nexalin Technology's Strong Financial Position: No Defaults on Senior Securities

Nexalin Technology (NXL) released a letter to shareholders from its CEO Mark White: "I am pleased to provide an update on Nexalin Technologies' rec...

Nexalin Technology releases letter to shareholders

Nexalin Technology (NXL) announces that its proprietary Deep Intracranial Frequency Stimulation technology is prominently featured in a newly publi...

Nexalin Technology announces peer-reviewed publication on DIFS technology

AAGR

COSM

ELTX

SOUN

Press Releases

New Study Shows Nexalin's Deep Intracranial Frequency Stimulation (DIFS) Significantly Improves Memory and Cognitive Function in Alzheimer's Patients

Nexalin Technology Announces Planned Clinical Trial Utilizing Gen-3 Halo Headset in Partnership with UC San Diego & San Diego VA

Nexalin Technology and Calidi Biotherapeutics Interviews to Air on the RedChip Small Stocks, Big Money(TM) Show on Bloomberg TV

NASDAQ Stocks Under $1 to Watch in October 2024: LGCB, KAVL, NXL, NXU, FAMI

Nexalin Technology Announces Landmark Study on Alzheimer's Disease  and Deep Intracranial Frequency Stimulation Published in Journal of Alzheimer's Disease

LOBO EV and Nexalin Technology Interviews to Air on the RedChip Small Stocks, Big Money(TM) Show on Bloomberg TV

Nexalin Technology Regains Compliance with Nasdaq Continued Listing Requirements

Join Nexalin Technology's Exclusive Live Investor Webinar and Q&A Session on November 5th

Nexalin Technology CEO Provides Letter to Shareholders

New Peer-Reviewed Publication Validates Nexalin's Deep Intracranial Frequency Stimulation (DIFS) Technology, Reinforcing Leadership in High-Growth Neuromodulation Market

Comments

Nexalin Technology

ニュース

最新ニュース Nexalin Technology (NASDAQ:NXL) 株価情報

こんな人も見ています

ニュース

パートナーシップ

ベンジンガ・グローバル